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Abstract 
 
Biobehavioral Relationships and Health Related Quality of Life in Persons  
with End Stage Renal Disease on Hemodialysis  
By Avis K. Allen, PhD, RN 
Director:  Nancy L. McCain, DSN, RN, FAAN, Professor 
A dissertation submitted in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2011 
 
The study of immune status and biobehavioral measures is limited in professional 
nursing. The purpose of the pre-pilot study was to describe levels of cytokines prior to, during, 
and after dialysis, examine changes in cytokine levels from immediate pre-dialysis to immediate 
post-dialysis, and to compare cytokine patterns prior to and after dialysis.  
A within subject descriptive study was conducted as part of a larger pilot study to 
describe levels of cytokines prior to, during, and after dialysis, examine changes in cytokine 
levels from immediate pre-dialysis to immediate post-dialysis, and to compare cytokine patterns 
prior to and after dialysis. Serum cytokine samples were collected pre-dialysis and every 30 
minutes during the dialysis treatment and immediately post-dialysis from a convenience sample 
of 10 patients. Mean age of subjects was 53.5 years and 60% were African American. The 
sample was equally divided between female and male. Statistical analysis using a nonparametric 
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paired difference test showed that only MIP-1β showed a significant increase from pre-dialysis 
to post-dialysis. Based on the results of this study, a second descriptive study was conducted. 
 The purpose of the second study was to examine the relationships among disease related 
factors, perceived stress, depressive symptoms, immune indicators, and HRQOL among patients 
requiring hemodialysis for ESRD using a PNI framework. Using a descriptive design, 
participants completed the Perceived Stress Scale (PSS), the Center for Epidemiologic Studies 
Depression Scale (CES-D), and one quality of life measure, the Functional Assessment of 
Cancer Therapy-General scale (FACT-G),  during the first hour of the dialysis treatment. In 
addition, blood samples were collected immediately prior to dialysis for cytokine measurement 
and demographic information was collected from the medical record.  
The sample included 75 adults with ESRD requiring dialysis who consented and were 
enrolled in the study. Regression analysis showed significant correlations among the 
psychosocial variables (p = <0.0001, r = 0.65). Negative correlations were found between 
perceived stress and health-related quality of life (p = 0.024) and depressive symptoms with 
health-related quality of life (p = 0.0003). MIP-1 ß was the only cytokine significantly (and 
positively) correlated with health-related quality of life ( p =  0.0419).  Principal component 
analysis of the cytokine data revealed three factors.  A three-factor solution described the 
cytokine data; Factors 1 and 3 represented a pro-inflammatory response and Factor 2 represented 
a mixture of pro-inflammatory and anti-inflammatory responses. There was a significant 
correlation between Factor 1 and depressive symptoms (p = 0.0069). Significant differences in 
the distributions of Factors 2 and 3 were associated with the presence of cardiovascular disease 
(CVD) (Chi-square = 4.0, df = 1, p = 0.047), (Chi-square = 4.1, df = 1, p = 0.043), respectively, 
and Factor 3 with hypertension (HTN) (Chi-square = 7.6. df = 1, p = 0.006). However no 
3 
 
relationships were found between the cytokine factors and QOL, PSS, and other variables. 
Findings suggest that there are relationships among psychosocial variables and possibly 
biological interactions that may affect perceptions of health-related quality of life among persons 
with ESRD on hemodialysis. 
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CHAPTER 1:  Overview 
 
End Stage Renal Disease (ESRD) is a chronic disease that creates both physical and 
psychological stressors (Kring & Crane, 2005; Tsay, Lee, & Lee, 2005). Factors associated with renal 
failure, the accumulation of uremic toxins, and the dialysis treatment itself can produce a chronic 
inflammatory state in patients on hemodialysis (Piroddi et al., 2007). Heart rate and blood pressure, 
natural killer cell activity, and the concentration of some lymphocytes increase during acute 
stress (Glaser & Kiecolt-Glaser, 2005), assisting the body to cope with the stressor. Physiologic 
measures normally return to equilibrium or allostasis over time.  However, in ESRD return to 
equilibrium is inhibited, leading to an internal state of chronic stress (Cukor, Cohen, Peterson & 
Kimmel, 2007). Chronic stress can lead to disorders of the body (McEwen, 2008). In dialysis 
patients elevated pro-inflammatory cytokine levels, particularly IL-6 and C-reactive protein 
(CRP) have been implicated in vascular disease events and mortality (Cazzavillan, et al., 2007; 
Lentine, Parsonnet, Taylor, Wrone, & Lafayette, 2006), as well as malnutrition (Ibrahim & 
Salamony, 2008; Koo, et al., 2003). Psychological changes have been connected to cytokine 
levels as well, resulting in depression and decreased quality of life (Dervisoglu, Kir, Kalender, 
Eraldemir, & Caglayan, 2007). Snaedal et al. (2009) reported finding a correlation between 
comorbidity and IL-6, supporting the theory that IL-6 is a strong predictor of cardiovascular 
disease. Studies measuring cytokine levels during hemodialysis have reported conflicting results and few 
studies examined large numbers of cytokines. However, elevated levels of cytokines have been reported 
in hemodialysis patients (Cazzavillan, et al., 2007; Ibhrahim & Salamony, 2008; Sertic et al., 2007). 
There have been no known studies that measured a full panel of cytokines throughout the dialysis 
treatment.   
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Perceived stress, immune functioning, depressive symptoms, and disease-related factors 
can affect the health-related quality of life (HRQOL) of patients on hemodialysis. Health-related 
quality of life (HRQOL) remains lower and mortality rates remain higher for patients with ESRD than for 
the general population. Research indicates that hemodialysis patients with lower HRQOL were at higher 
risk of hospitalization and death (Mapes et al., 2003). Depression is the most common psychological 
problem reported by hemodialysis patients (Lopes et al., 2004) and has been linked with various health 
problems, including cardiovascular disease and malnutrition-inflammation complex (Cukor, Cohen, 
Peterson, & Kimmel, 2007; Ibrahim & Salamony, 2008; Koo et al., 2003). Stressors negatively affect the 
HRQOL of patients and can lead to depression and increased morbidity and mortality (Kimmel & 
Peterson, 2006; Ye et al., 2008). 
ESRD changes the immune system in ways that are not completely understood.  In 
summary, there appear to be correlations between perceived stress, immune functioning, 
depressive symptoms, and HRQOL, but the nature of such relationships is not well documented. 
All of these factors contribute to long-term outcomes for patients with ESRD. With mortality 
rates of greater than 20%, increased understanding of these relationships is important in order to 
develop biobehavioral interventions to improve outcomes.  Psychoneuroimmunology (PNI) is 
the study of the interaction of the central nervous system (CNS), endocrine system, and immune 
system (Yang & Glaser, 2002).  The PNI framework explains the physical and psychobehavioral 
interactions that affect the immune system (McCain, Gray, Walter, & Robins, 2005).  For 
example, behavioral factors are believed to moderate the immune system through 
neuroendocrine system changes.  PNI is a comprehensive model incorporating individual, 
environmental, physiological and spiritual factors and effectively grounds both qualitative and 
quantitative methods.   
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A within-subject descriptive study was conducted as part of a larger pilot study to 
describe levels of cytokines prior to, during, and after dialysis, examine changes in cytokine 
levels from immediate pre-dialysis to immediate post-dialysis, and to compare cytokine patterns 
prior to and after dialysis. Serum cytokine samples were collected pre-dialysis and every 30 
minutes during the dialysis treatment and immediately post-dialysis from a convenience sample 
of 10 patients. Mean age of participants was 53.5 years and 60% were African American. The 
sample was equally divided between females and males. Statistical analysis using a 
nonparametric paired difference test showed that only MIP-1β significantly increased from pre-
dialysis to post-dialysis.  
The purpose of the second study was to examine the relationships among disease-related 
factors, perceived stress, depressive symptoms, immune indicators, and HRQOL among patients 
requiring hemodialysis for ESRD using a PNI framework. The study utilized a cross-sectional 
design to investigate factors potentially associated with the stress of undergoing hemodialysis. 
Few studies have addressed these factors measured simultaneously and viewed from an 
integrated, holistic perspective.  
The sample was predominantly Black (75.7%) and male (65%) with a mean age of 53.9 (range 
23-83). Mean time that participants had been on dialysis was 3.0 years with a range of less than 1 month 
to 20.8 years. Most had been diagnosed with hypertension (85%) and diabetes (59%). Mean levels of 
perceived stress were 15.9 (SD = 8.0), levels of depressive symptoms were 16.2 (SD = 12.7), and levels of 
HRQL were 68.1 (SD = 14.2). Regression analysis showed significant correlations among the 
psychosocial variables (p = <0.0001, r = 0.65). Negative correlations were found between perceived 
stress and health-related quality of life (p = 0.024) and depressive symptoms with health-related quality of 
life (p = 0.0003). MIP-1ß was the only cytokine significantly (and positively) correlated with health-
related quality of life (p =  0.0419).  Principal component analysis of the log-transformed cytokine data 
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revealed three factors: Factors 1 and 3 represented a pro-inflammatory cytokine pattern and Factor 2 
represented a mixture of pro-inflammatory and anti-inflammatory cytokines. A one-way analysis of 
variance (ANOVA) revealed a significant correlation (p = 0.0069) between Factor 1 and depressive 
symptoms. Significant differences in the distributions of Factors 2 and 3 were associated with the 
presence of cardiovascular disease (CVD) (Chi-square = 4.0, df = 1, p = 0.047), (Chi-square = 4.1, df = 1, 
p = 0.043), respectively, and Factor 3 with hypertension (HTN) (Chi-square = 7.6. df = 1, p = 0.006). 
However no relationships were found between the cytokine factors and QOL, PSS, and other variables. 
Study findings suggest that there are relationships among psychosocial variables rand possibly biological 
interactions that may affect persons with ESRD on hemodialysis perceptions’ of health-related quality of 
life. Further studies with larger sample could provide direction for evaluating the relationship 
between stress, depressive symptoms, immune functioning and HRQOL. Larger studies could 
provide guidance toward interventions to improve HRQOL for patients on hemodialysis for 
ESRD. 
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CHAPTER 2:  Cytokine Patterns during Hemodialysis 
 
Abstract 
The study of immune status and biobehavioral measures is limited in professional 
nursing. The purpose of the pre-pilot study was to describe levels of cytokines prior to, during, 
and after dialysis, examine changes in cytokine levels from immediate pre-dialysis to immediate 
post-dialysis, and to compare cytokine patterns prior to and after dialysis.  
A within subject descriptive study was conducted as part of a larger pilot study to 
describe levels of cytokines prior to, during, and after dialysis, examine changes in cytokine 
levels from immediate pre-dialysis to immediate post-dialysis, and to compare cytokine patterns 
prior to and after dialysis. Serum cytokine samples were collected pre-dialysis and every 30 
minutes during the dialysis treatment and immediately post-dialysis from a convenience sample 
of 10 patients. Mean age of subjects was 53.5 years and 60% were African American. The 
sample was equally divided between female and male. Statistical analysis using a nonparametric 
paired difference test showed that only MIP-1β showed a significant increase from pre-dialysis 
to post-dialysis.  
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Cytokine Patterns during Hemodialysis 
End Stage Renal Disease (ESRD) is a chronic disease that creates both physical and 
psychological stressors including fatigue, muscle cramps, hypotension, diet and fluid restrictions, 
and physical limitations (Gurklis & Menke, 1995; Tsay, Lee, & Lee, 2005; Welch & Austin, 
2001). Factors associated with renal failure and the accumulation of uremic toxins and factors 
associated with the dialysis treatment itself can produce a chronic inflammatory state in dialysis 
patients. The kidneys help regulate pro-inflammatory and pro-oxidant factors through clearance, 
however the dialysis procedure does not completely replace the functions of the kidney (Piroddi 
et al., 2007).  Furthermore, impaired lymphocyte function is a result of both the uremic state and 
dialysis therapy. Lymphocyte subsets and monocytes change into pro-inflammatory phenotypes, 
resulting in an overproduction of cytokines. Elevated levels of IL-6, in particular are associated 
with cardiovascular disease, malnutrition and muscle wasting in ESRD patients (Piroddi et al., 
2007). Dialysis-dependent factors associated with inflammation include bioincompatability of 
the dialyzer, exposure to bacterial contamination due to dialysis fluid contamination, and use of 
drugs such as iron and erythropoietin.  
Cytokines in End-Stage Renal Disease 
Research studies about cytokine patterns during hemodialysis treatment have primarily 
focused on investigating the relationship between complement activation and dialyzer 
membranes. Dialyzer membranes have been shown to activate the complement system, 
particularly the early membranes made with bioincompatible materials such as cuprophan 
(Andreoli et al., 2007; Grooteman et al., 1995; Lee, Hakim, and Fearon, 1984; Lonnemann, 
Koch, Shaldon, and Dinarello, 1988; Varela et al., 2001). Lonnemann et al. (1988) hypothesized 
that monocytes adhering to the membrane were exposed to endotoxins and C5a from dialysate, 
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inducing IL-1 production, causing a response similar to an acute phase response. Sertic et al. 
(2007) reported that levels of IL-6, IL-8, IL-10, TNF-α, IL-1β, and MCP-1 were significantly 
higher in chronic hemodialysis patients compared to healthy control subjects.  
Varela et al. (2001) investigated circulating levels of IL-1β, IL-2, C3a and C5a before 
and after, and at 15, 30, and 50 minutes during a dialysis treatment with one of three randomly 
assigned dialyzers.  Levels of IL-1β increased from before to after dialysis in all three groups but 
varied in the amount of increase seen, suggesting that IL-1β was a good marker for measuring 
dialyzer incompatability. However, Grooteman, et al. (1995) in a dialyzer comparison study, 
reported that IL-1β and IL-6 were not detected at all but they found a slight decrease in 
leukocytes, particularly CD8+ cells. 
Lee, Hakim, and Fearon (1984) measured complement activation comparing new and 
reused dialyzers with cellulosic membranes and new dialyzers with PMMA membranes. 
Activation of the complement system was evaluated by comparing the expression of C3b 
receptor on neutrophils predialysis, and at timed intervals of 10, 20, 60, and 120 minutes after the 
start of the dialysis treatment. The authors reported increased expression of C3b receptor by 
neutrophils and generation of increased C3a with the cellulosic dialysis membrane, both new and 
reused versus modest increases with the Polymethylmethacrylate (PMMA) membrane. However, 
this was a very small sample with 4 patients in each arm of the study. 
Grooteman, et al. (1995) compared the biocompatibility of dialyzers with cellulose-
triacetate (CTA) and polysulphon (PS) membranes. Blood samples were taken at 7.5, 15, 30, and 
180 minutes after dialysis began and biocompatibility was measured by analysis for leukocytes, 
lymphocyte subpopulations, C3a, C5a, IL-1β, IL-6, and TNFα. Results showed a decrease in 
lymphocytes during the first 15 minutes of treatment for both membranes but were significantly 
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greater with the CTA membrane. In a similarly designed study, Andreoli et al. (2007) compared 
a dialyzer with cellulosic membrane with a dialyzer with a synthetic membrane (polysulfone) in 
a crossover design. The aim of the study was to compare the effect of each type of membrane on 
apoptosis, cytokine serum levels, polymorphonuclear cells (PMN), complement activation and 
synthesis by peripheral blood mononuclear cells (PBMC) Baseline blood samples were drawn 
predialysis at the beginning of the study and at the end of the trial period with each dialyzer. 
Blood samples were analyzed for PMN, CRP, C3a and terminal complement complex (TCC), 
TNF-α, and IL-10.  They found no differences in complement activation between membranes.  
Caglar et al. (2002) investigated the dialysis procedure itself as a source of inflammation 
in hemodialysis patients. Inflammation was assessed in hemodialysis patients during a treatment 
by drawing samples for CRP, IL-6, albumin FSR, and fibrinogen FSR from 2 hours before the 
treatment, through the treatment and 2 hours after the treatment. Findings included increased 
albumin FSR and fibrinogen FSR throughout the dialysis treatment and continued increase in 
fibrinogen FSR during the 2-hour post-dialysis period. Albumin FSR decreased slightly during 
the 2 hour post-dialysis period. A modest increase in IL-6 was seen throughout the dialysis 
treatment but a greater increase was seen from end of treatment to 2-hours post-treatment. The 
authors reported a weak correlation between change in the fibrinogen FSR level and the extent of 
change in IL-6. 
Snaedal et al. (2009) investigated the relationship between comorbidities and 
inflammation, measuring CRP, IL-6, IL-10, and TNF-α from hemodialysis patients over a 12-
week period in a group of 254 chronic hemodialysis patients in Sweden. The authors identified 
the following comorbidities in their study population: malignancy, ischemic heart disease, 
peripheral/cerebral vascular disease, congestive heart failure, diabetes mellitus, and systemic 
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collagen disease. CRP was found to be highly variable within patients but the authors reported a 
correlation between comorbidites and increased levels of CRP and IL-6.  No significant 
correlations with IL-10 and TNF-α were found.  
Tarakcioglu, Erbagci, Usalan, Deveci & Kocabas (2003) compared cytokine levels pre 
and post dialysis. The authors reported a significant decrease in IL-8 from predialysis to 
postdialysis but found no change in IL-1β, sIL-2R, IL-6, and TNF-α. In contrast, Raj et al. 
(2007) analyzed blood samples drawn from eight hemodialysis patients pre- and post-dialysis. 
IL-6, CRP and TNF-α results were reported in this study. IL-6 levels increased significantly but 
not CRP or TNF-α.  
In summary, studies have reported conflicting results in changes in pre/post or intra 
cytokines. Increases in IL-6 were reported in two studies, two reported increases in IL-1, and 
increases in TNF-α, IL-2, and IL-8 were separately reported in three studies. Few studies 
examined large numbers of cytokines and a variety of methods were used to measure cytokines. . 
Past research has focused primarily on how dialyzer membranes affect specific cytokines and 
studies have reported varying results. Comparisons are difficult because different cytokines were 
measured in each study and conflicting results are reported for those studies that did include the 
same cytokines. In addition, many advancements have been made in the technology used in the 
care of patients with ESRD. The bulk of prior research has been conducted with bioincompatable 
membranes, particularly cupraphan. Dialyzer membranes have advanced to much more 
biocompatible materials. Therefore, it is important to reexamine cytokine changes in dialysis as 
possible contributors to an inflammatory state. 
 
 
16 
 
 
Table 1.  Summary of Findings in the Literature Related to Changes in Cytokines During 
Hemodialysis Treatments 
 
First Author/Date Method Medium  Cytokine 
increased 
Lee/1984 
Lonnemann/1988 
 
Grooteman/1995 
Varela/2001 
 
Caglar/2002 
Tarakcioglu/2003 
Raj/2007 
 
Radioimmunoassay 
Radioimmunoassay 
 
Immunoassay 
Elisha 
 
Elisha 
Immunoassay 
Elisha 
Serum 
In vitro with 
MNC 
Serum 
Serum 
 
Serum 
Serum 
Serum 
 
C3a 
IL-1 
 
TNFα 
IL-1 
IL-2 
IL-6 
IL-8 
IL-6 
 
 
Study Purpose 
 To date, no studies have been found that describe cytokine patterns throughout the entire 
dialysis treatment. Most studies have measured limited, selected cytokines before and after 
dialysis. Given the paucity of published information on cytokine patterns during hemodialysis, 
this study was undertaken to (1) describe levels of cytokines prior to, during, and after dialysis; 
(2) examine changes in cytokine levels from immediate pre-dialysis to immediate post-dialysis; 
and (3) compare cytokine patterns prior to and after dialysis. 
Design and Methods 
This within-subject descriptive study was conducted in the Acute Dialysis Clinic (ADC) 
within an academic medical center as part of a larger pilot study to determine the optimal time in 
the dialysis treatment period to collect blood samples for measurement of cytokine levels.  
Participants were screened and consented during dialysis and data were collected on their 
subsequent dialysis day. The dialyzer used in the treatments was a Gambro Polyflux L dialyzer, a 
low-flux dialyzer with a polymix membrane, a biocompatible material. Ten adult patients (≥ 21 
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years) admitted to the ADC who are able to give informed consent and who understood and 
spoke English were eligible for the study. Participants were consented by the nurse manager of the 
ADC and assigned an arbitrary subject code. A trained RN research assistant collected 2 ml of blood from 
subjects’ existing indwelling catheters immediately pre-dialysis, every 30 minutes during dialysis, and 
immediately post-dialysis for a total of 9 sample collections for each subject. Plasma samples were 
cryopreserved and batch- analyzed by highly experienced personnel using a Bio-Plex® (Bio-Rad, Inc.) 
system.   
Laboratory Procedures 
A Bio-Plex® multiplex suspension array system in the Center for Biobehavioral Clinical 
Research (P20 NR008988), VCU School of Nursing, was used by highly experienced personnel 
to simultaneously measure plasma levels of 17 cytokines across the dialysis period for each 
subject. Bio-Rad’s Human 17-Plex® bead array panel was used to measure levels of IL-1ß, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, granulocyte-colony stimulating factor 
(G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IFN-γ, 17onocytes 
chemotactic protein-1 ( MCP-1), macrophage inflammatory protein-1 beta (MIP-1ß), and TNF-α 
at each of the 9 study timepoints. 
Data Analysis 
Descriptive statistics including means, standard deviations, medians, minimum and 
maximum values were computed for each cytokine at each of the 9 measurement time points 
during dialysis.  Individual patterns in cytokine were examined graphically over the study period 
and normality for each measure assessed. In addition, overall mean, or for non-normal data, 
median values were plotted to examine group values over time. Random effects mixed models 
were used to describe the pattern of change for each cytokine over time. These analytic models 
are advantageous because they incorporate the dependencies between the repeated measures 
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within each subject over time. The change in cytokine values was described through the slope of 
the fitted model to ascertain whether cytokines generally increase or decrease across dialysis. 
Further, immediately post-dialysis cytokine levels were compared to the pre-dialysis values for each 
cytokine measure. Contrasts created from the random effects model estimated and tested the change from 
pre- to post-dialysis. Analyses were completed using SAS v9.1 and assumed alpha = 0.05 for statistical 
significance. 
Results 
Sample 
 Mean age of subjects was 53.5 with a range of 36-66 years and 60% were African 
American, 40% Caucasian, and one subject of Hispanic ethnicity. Subjects were equally divided 
between females and males. Eight of the 10 subjects had a history of hypertension (HTN) and 3 
had been diagnosed with diabetes mellitus (DM). In addition, 3 had a history of cardiovascular 
disease. One subject had a history of Hepatitis C and had a hip wound at the time of the study.  
Log values for each cytokine were used in analysis. Most of the values for IL-10 were 
below the limit of detection, thus IL-10 was not included in the panel for analysis. Further, one 
subject was removed from the group analyses because the biomarker values were so much higher 
for this individual in comparison to the other subjects. Thus, analyses were conducted for 9 
subjects. 
Examined individually, only IL-4 and MIP-1ß levels changed significantly over the 
dialysis period. In average log values, there was a significant decrease of 0.05 in IL-4 (p = 
0.036), and a significant increase of 0.08 in MIP1β (p = 0.015) every 30 minutes over the course 
of dialysis. Levels of G-CSF decreased an average of 0.05 every 30 minutes over dialysis and 
this change approached significance (p = 0.054).  
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 Paired differences were computed to compare biomarker values from pre-dialysis to post-
dialysis (instead of observing the trend over the course of dialysis). Due to the small sample size 
and non-normality of the markers, a nonparametric paired difference test was conducted. Only 
MIP-1ß had a significant increase of 88.6 pg/ml from the initiation to completion of dialysis. G-
CSF exhibited a marginally significant decrease with a p-value of 0.055 (Table 1). 
Table 2. Differences in Cytokine Levels: Pre- vs. Post-dialysis 
 
   Mean                    
Difference 
 
  Median 
 
    SD 
 
     p-value 
 
GCSF -25.80 -23.93 33.43 0.0547 
GMCSF -0.73 0.00 7.73 0.8433 
IFNγ -15.88 0.00 42.16 0.3125 
IL2 -0.36 1.1 4.97 0.98 
IL4 -0.39 0.00 0.85 0.3125 
IL5 -0.87 0.00 2.06 0.3125 
IL6 1.77 0.66 4.58 0.3594 
IL7 0.87 0.34 2.37 0.5469 
IL8 4.83 2.82 6.87 0.0742 
IL12 2.43 0.76 4.43 0.1953 
IL13 0.07 0.00 2.92 0.9063 
IL1b -0.11 0.00 0.52 0.6875 
MCP1 11.23 2.23 22.64 0.2031 
MIP1β 96.67 88.61 93.89   0.0039* 
TNFα -4.16 4.01 15.84 0.7422 
 
 
When graphed using individual profile plots (Figure 1) cytokine patterns appear fairly 
similar, with the same cytokines spiking at the beginning and the end of dialysis; however, there 
are some noticeable differences in the magnitude of the observed values in these individuals.  
There are overall increases in values for MIP-1β and MCP-1 from pre- to post-dialysis, while the 
magnitude of values decline for G-CSF and IFNγ, although fewer individuals have larger values 
of IFNγ. All individuals experienced increases in values of IL-8 and MIP-1β.  Values of IL-2, 
IL-4, IL-5 and IL-1β remained low at both the beginning and end of dialysis. 
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Figure 1. Cytokine Patterns Pre- and Post-dialysis 
 Pre-dialysis Post-dialysis 
* MIP1b value plotted at 250mg/dL is rescaled from actual value of 455.63mg/dL 
 
Discussion 
 Previous research in the hemodialysis population has focused primarily on investigating 
the effect of different dialyzer membranes on selected pro-inflammatory cytokines. Recent 
research has demonstrated that labeling cytokines as either pro-inflammatory or anti-
inflammatory may not be accurate because the various cytokines have interdependent and 
pleotropic effects. Cytokine activity may be influenced by many factors such as the nature of the 
target cells, growth and activation state of the cells, and concentrations (Navarro-Gonzalez & 
Mora-Fernandez, 2008; Xing &Wang, 2000). Many cytokines also have multiple functions and 
those functions may be shared by other cytokines, possibly creating synergistic effects on cells. 
Additionally, methods of analyzing cytokines have improved in the interim since many of these 
studies were completed, with current methods being much more sensitive as well as reliable and 
accurate. Inconsistent results have been reported in past research. CRP has been used extensively 
to measure inflammatory response but CRP is highly variable within patients (Snaedal et al., 
2009).  IL-1, IL-2, IL-6, and TNF-α have been measured pre-dialysis and post-dialysis with 
varying results.   
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 Levels of IL-10 were not detectable in this study and were not included in the analysis, in 
contrast to the findings of Sertic et al. (2007). Significant changes were seen in IL-4 and MIP-1β 
over the course of dialysis and the changes in G-CSF approached significance. When values 
were compared pre-dialysis to post-dialysis, only MIP-1β showed a significant increase.    
 Our first purpose was to describe patterns of cytokines during dialysis. There was little 
change in most cytokines over the course of the hemodialysis treatment with the exception of IL-
4, and MIP-1β. The decrease in IL-4, an anti-inflammatory cytokine due to its ability to suppress 
pro-inflammatory cytokines and chemokines (Dinarello, 2000) may have had an effect on MIP-
1β, a chemokine that increased over the course of dialysis. Removal of certain cytokines by some 
dialyzers with adsorption properties has been documented in some studies (Randoux et al., 
2001), possibly explaining the decrease in IL-4.   
Our second purpose was to examine changes in cytokines from immediately pre-dialysis 
to immediately post-dialysis. Only MIP-1β increased significantly from pre-dialysis to post-
dialysis. MIP-1β has been shown to stimulate atherosclerosis in hypertensive patients and 
proposed as an independent predictor for stroke and cardiovascular disease in this patient 
population (Tatara, Ohishi, Yamamoto, et al., 2009). It was of interest that IL-6 did not change 
significantly from pre-dialysis to post-dialysis. Increased IL-6 has been linked with 
cardiovascular disease in patients with ESRD (Piroddi, Depunzio, Calabrese, et al., 2007), but 
perhaps previous findings expressed less sensitive or accurate levels of IL-6. Since the authors 
did not have a control group, IL-6 levels may have been chronically elevated. A comparison of 
IL6 with nondialysis patients might provide further insight. Further, a focus on singular 
cytokines is likely to be less informative than the view of patterns among cytokines.  
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In examining the third research purpose, the patterns of cytokines pre- vs. post-dialysis 
were not found to be appreciably different. As seen in Figure 1, the post-dialysis spikes in MIP-
1β and MCP-1 were slightly higher than at pre-dialysis, but the patterns per se did not differ. 
Based on our findings, cytokines may be drawn at any point during the dialysis treatment. This is 
in contrast to the results of other studies cited here (see Table 1). 
 The steady increase in MIP-1β throughout the hemodialysis treatment was very 
interesting.  Results here contrast with previous studies performed across the dialysis treatment. 
Improvements in dialysis technology and sensitivity of instruments measuring cytokine levels 
may explain some of the differences. Improvements in dialyzer materials to more biocompatible 
materials could also explain some of the differences. Patient characteristics and comorbidities 
may also have been a contributing factor. However, more research is needed to determine if 
results can be replicated and to investigate causes of this phenomenon.  
This was a small study in an urban group of patients with results that conflict with prior 
studies. Without a control group it is not possible to know if predialysis levels were more 
elevated or depressed at baseline. Time on dialysis, prior transplant status, medication, 
demographics, and patient characteristics are other variables that could have affected the 
cytokine levels of this group of subjects. Further research is needed to investigate cytokine 
patterns in a larger study to learn more about this phenomenon.       
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agents of the institutions] that are not under the authority of VCU or VCU Health 
Systems and are located within the United States or a United States territory) in your 
research project?  
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-6.htm 
 
14. Do you plan to involve FOREIGN RESEARCH SITES (i.e., institution or non-institutional  YES *  NO 
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setting)? 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-11.htm 
 
15. Do you plan to involve INDEPENDENT INVESTIGATORS (i.e., individuals who are not 
representatives of VCU or any other institution or facility) in your research project? 
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-15.htm 
 
16. Does this project involve the creation of a HUMAN SUBJECTS REGISTRY (registries are 
sometimes called repositories, data sets, data banks, tissue or specimen banks) as an 
instrument for the conduct of research? 
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-4.htm 
 
17. Does this project involve GENETIC TESTING, that is, testing human tissue samples for 
heritable characteristics or storing human tissue samples for possible future such testing? 
 YES *  NO 
* If YES, you must follow guidance at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-5.htm 
 
Section 8: Research Subject Information 
 
VULNERABLE SUBJECTS: 
Consider your criteria for inclusion or exclusion of any subpopulation, review the following information, and identify 
research categories (as appropriate). 
 
BOX 1: CHILDREN: If you plan to allow for the inclusion of data on subjects who are children, you must indicate the 
inclusion of their data and identify a research category or categories below.  
NOTE: In Virginia, children are those under the age of 18 and not emancipated.  
 
Do you plan to allow for the inclusion of data on subjects who are children?                                        YES *  NO 
* If YES, identify the research category or categories below. 
 
  Research not involving greater than minimal risk (45 CFR 46.404) – [NOTE: see definition of minimal risk below] 
 
  Research involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects 
(45.CFR 46.405) 
 
  Research involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to 
yield generalizable knowledge about the subject’s disorder or condition. (45.CFR 46.406)1 
 
  Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious 
problem affecting the health or welfare of children. (45.CFR 46.407)1 
 
MINIMAL RISK means that the probability and magnitude of harm or discomfort anticipated in the research are not greater 
in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or 
psychological examinations or tests. 
 
1 Categories 406 and 407 REQUIRE BOTH parents to provide permission for the child’s participation unless one is 
deceased, unknown, incompetent, or only one parent has legal responsibility for care and custody. The IRB may 
determine that permission of both parents is required for categories 404 or 405. 
 
NOTE: If you plan to allow for the inclusion of data on subjects who are children, you must include the VCU IRB CHILDREN-
SUBJECT FORM with your submission if you are requesting an expedited or full board review. The form is available at 
http://www.research.vcu.edu/forms/vcuirb.htm 
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BOX 2: PREGNANT WOMEN, HUMAN FETUSES, AND NEONATES: If you plan to allow for the inclusion of data on 
subjects who are pregnant women, human fetuses, or neonates as subjects, you must indicate inclusion of their data and 
identify a research category or categories below. 
 
Do you plan to allow for the inclusion of data on subjects who are PREGNANT WOMEN, 
HUMAN FETUSES, or NEONATES as subjects?                                      
 YES *  NO 
* If YES, identify the research category or categories below. 
 
  Research involving pregnant women or fetuses [PW-HF-N (45.CFR46.204)] 
 
  Research involving neonates of uncertain viability and nonviable neonates [PW-HF-N (45.CFR46.205(a)(b)(c))] 
 
  Research involving neonates of certain viability [PW-HF-N (45.CFR46.205(d))] 
 
  Research involving after delivery, the placenta, the dead fetus or fetal material[PW-HF-N (45.CFR46.206)] 
 
  Research not otherwise approvable, which presents an opportunity to understand, prevent, or alleviate a serious 
problem affecting the health or welfare of pregnant women, fetuses, or neonates [PW-HF-N (45.CFR.46.207)] 
 
NOTE: If you plan to allow for the inclusion of data on subjects who are pregnant women, fetuses, or neonates you must 
include the VCU IRB PREGNANT WOMEN, FETUSES, NEONATES-SUBJECT FORM with your submission if you are requesting an 
expedited or full board review.  The form is available at http://www.research.vcu.edu/forms/vcuirb.htm 
 
 
BOX 3: PRISONERS: If you plan to allow for the inclusion of data on subjects who are, or may become, a prisoner, you 
must indicate that you plan to allow for inclusion of their data and identify a research category below.  NOTE: If an 
enrolled research subject becomes incarcerated (or otherwise meets the definition of prisoner) during the course of 
an IRB approved project, the PI must immediately notify the IRB and amend the protocol to allow for the 
inclusion of prisoners and the continuation of that subject.  If this should occur, you must follow the VCU IRB 
PRISONER-SUBJECT GUIDANCE and include the VCU IRB PRISONER-SUBJECT FORM with your submission to the 
IRB.  The guidance and form are available at http://www.research.vcu.edu/forms/vcuirb.htm 
 
Do you plan to allow for the inclusion of data on subjects who are, or may become a 
PRISONER?  
 YES *  NO 
* If YES, identify the research category below.                               
 
  Research involving study of the possible causes, effects, and processes of incarceration, and of criminal behavior, 
provided that the project presents no more than minimal risk and no more than inconvenience to the subjects 
(45.CFR 46.306(a)(2)(i)) – [NOTE: see definition of minimal risk below] 
 
  Research involving study of prisons as institutional structures or of prisoners as incarcerated persons, provided that 
the project presents no more than minimal risk and no more than inconvenience to the subjects (45.CFR 
46.306(a)(2)(ii)) – [NOTE: see definition of minimal risk below] 
 
  Research on conditions particularly affecting prisoners as a class (for example, vaccine trials and other research on 
hepatitis which is much more prevalent in prisons than elsewhere; and research on social and psychological 
problems such as alcoholism, drug addiction, and sexual assaults) provided that the project may proceed only after 
the Secretary (through OHRP) has consulted with appropriate experts including experts in penology, medicine, and 
ethics, and published notice, in the Federal Register, of his intent to approve such research (45.CFR 
46.306(a)(2)(iii)) 
 
  Research on practices, both innovative and accepted, which have the intent and reasonable probability of 
improving the health or well-being of the subject.  In cases in which those studies require the assignment of 
prisoners in a manner consistent with projects approved by the IRB to control groups which may not benefit from 
the research, the project may proceed only after the Secretary (through OHRP) has consulted with appropriate 
experts including experts in penology, medicine, and ethics, and published notice, in the Federal Register, of his 
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intent to approve such research (45.CFR 46.306(a)(2)(iv)) 
 
  Research defined as public health research that focuses on a particular condition or disease in order to (i) describe 
its prevalence or incidence by identifying all cases, including prisoner cases, or (ii) study potential risk factor 
associations, where the human subjects may include prisoners in the project population but not exclusively as a 
target group, provided that the project presents no more than minimal risk and no more than inconvenience to the 
subjects (Epidemiological Waiver Request) 
 
MINIMAL RISK AS IT PERTAINS TO THE PRISONER POPULATION means that the probability and magnitude of physical or 
psychological harm that is normally encountered in the daily lives or in the routine medical, dental, or psychological 
examination of healthy persons. 
 
NOTE: If you plan to allow for the inclusion of data on subjects who are, or may become, prisoners, you must follow the VCU 
IRB PRISONER-SUBJECT GUIDANCE and include the VCU IRB PRISONER-SUBJECT FORM with your submission.  The guidance 
and form are available at http://www.research.vcu.edu/forms/vcuirb.htm 
 
 
 
SUBJECT ENROLLMENT PLAN: 
 
Anticipated # OF SUBJECTS (if this is a multi-center project, list only subjects under this IRB approval): 75 
Is this a MULTI-CENTER 
PROJECT? 
 YES  NO 
If YES, please provide: 
(1) # OF SITES:       (2) # OF SUBJECTS ACROSS ALL 
SITES: 
      
 
 
CONSENT DOCUMENTATION: (Mark the type of consent process/documentation planned): 
 
  Since this project is being submitted for EXEMPT REVIEW, it does not include informed consent/assent documents. 
 
 STANDARD CONSENT FORM: A copy of the proposed consent form(s) is attached to this submission. 
 
  CONSENT FORM FOR PRISONER SUBJECTS: A copy of the proposed consent form for prisoners is attached to this 
submission. 
 
 WAIVER OF SOME OR ALL ELEMENTS OF CONSENT OR PARENTAL PERMISSION: NOTE: Waiver is not allowed 
for FDA-regulated research unless it meets FDA requirements for Waiver of Consent for Emergency Research (see 
below). A request is being made to waive the requirement to obtain prospective informed consent from subjects or 
permission from parents. Your research synopsis should explain why: (1) the research involves no more than 
minimal risk to the subjects, (2) the waiver or alteration will not adversely affect the rights and welfare of the 
subjects, (3) the research could not practicably be carried out without the waiver or alteration; AND (4) whether or 
not subjects will be debriefed after their participation.  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-1.htm. 
  
  WAIVER OF DOCUMENTATION OF CONSENT, PARENTAL PERMISSION:    
A request is being made to waive documentation of consent.  The IRB may waive this requirement if it finds 
either: (1) that the only record linking the subject and the research would be the consent document and the 
principal risk would be potential harm resulting from a breach of confidentiality. Subjects will be asked whether 
they want documentation linking them with the research, and each subject’s wishes will govern; or (2) that the 
research presents no more than minimal risk of harm to subjects and involves no procedures for which written 
consent is normally required outside of the research context. Your research synopsis should include a justification 
for waiver based on one of these two elements and include a description of the information that will be provided to 
participants.  If you are proposing to use a verbal consent statement, the proposed consent script should be attached 
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to this submission.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-2.htm  
 
  ASSENT FORM: A copy of the assent form for children or decisionally-impaired persons is attached to this 
submission.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XV-2.htm. and 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-7.htm. 
 
  WAIVER OF ASSENT: A request is being made to waive the requirement to obtain prospective assent from children 
age 7 or higher, or decisionally-impaired persons. Your research synopsis should explain (1) why some or all of the 
individuals  age 7 or higher, or decisionally-impaired will not be capable of providing assent based on their 
developmental status or impact of illness; (2) the research holds out a prospect of direct benefit not available 
outside of the research; AND/OR (3) [a] the research involves no more than minimal risk to the subjects, [b] the 
waiver or alteration will not adversely affect the rights and welfare of the subjects, [c] the research could not 
practicably be carried out without the waiver or alteration; AND [d] whether or not subjects will be debriefed after 
their participation.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XV-2.htm. 
 
 Waiver of Consent for Emergency Research:  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-16.htm. 
 
 
Section 9: VCU Research Plan 
 
You must use the VCU Research Plan Template that can be found at http://www.research.vcu.edu/forms/vcuirb.htm, 
Use of this template is required to provide your VCU Research Plan to the IRB. Your responses should be written in terms 
for the non-scientist to understand.  If a detailed research protocol (e.g., sponsor’s protocol) exists, you may reference that 
protocol.  NOTE: If that protocol does not address all of the issues outlined in each Section Heading, you must 
address the remaining issues in this Plan.  It is NOT acceptable to reference a research funding proposal.       
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VCU RESEARCH PLAN TEMPLATE 
 
Use of this template is required to provide your VCU Research Plan to the IRB.  Your responses should be written in terms 
for the non-scientist to understand.  If a detailed research protocol (e.g., sponsor’s protocol) exists, you may reference that 
protocol.  NOTE: If that protocol does not address all of the issues outlined in each Section Heading, you must address 
the remaining issues in this Plan.  It is NOT acceptable to reference a research funding proposal.       
 
ALL Sections of the Human Subjects Instructions must be completed with the exception of the Section entitled 
“Special Consent Provisions.”  Complete that Section if applicable.  When other Sections are not applicable, list the 
Section Heading and indicate “N/A.” 
 
NOTE: The Research Plan is required with ALL submissions and MUST follow the template, and include version 
number or date, and page numbers.   
 
DO NOT DELETE SECTION HEADINGS OR THE INSTRUCTIONS. 
 
I. TITLE    
 
 
BIOBEHAVIORAL RELATIONSHIPS IN PERSONS ON HEMODIALYSIS 
 
  
 
II. STAFFING 
A.  In the table below (add additional rows as needed), indicate: (1) key project personnel including the principal 
investigator and individuals from other institutions, (2) their qualifications, and (3) a brief description of their 
responsibilities. 
 
NAME OF INDIVIDUAL QUALIFICATIONS RESPONSIBILITIES 
Nancy L. McCain DSN, RN, FAAN, Professor VCU School 
of Nursing  
PI 
Avis Allen RN, MSN, CNN, NE-BC Co-investigator/PhD Candidate 
   
   
    
 
B.  Describe the process that you will use to ensure that all persons assisting with the research are adequately 
informed about the protocol and their research-related duties and functions. 
 
Prior to the beginning of the study, information sessions will be held for all persons involved in the research study. All 
persons involved in the research will be required to attend to inform them of the research protocol and their 
responsibilities.    
  
 
III. CONFLICT OF INTEREST 
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s participation in 
this project or completion of the project in general. Do not describe (1) academic recognition such as publications or 
(2) grant or contract based support of VCU salary commensurate with the professional effort required for the 
conduct of the project 
 
No benefit beyond academic recognition. 
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IV. RESOURCES 
Briefly describe the resources committed to this project including: (1) time available to conduct and complete the 
research, (2) facilities where you will conduct the research, (3 availability of medical or psychological resources 
that participants might require as a consequence of the research (if applicable), and (4) financial support. 
 
THE CO-INVESTIGATOR HAS ADEQUATE TIME ALLOCATED TO COMPLETE THE RESEARCH AND APPROVAL HAS BEEN 
OBTAINED FOR THE USE OF THE ACUTE DIALYSIS UNIT AT VCUHS AND THE RAI DIALYSIS UNIT.  MINIMAL RISK OF 
HARM IS ANTICIPATED AS A RESULT OF THE STUDY.  
 
 
 
V. HYPOTHESIS 
Briefly state the problem, background, importance of the research, and goals of the proposed project. 
 
 
Chronic kidney disease has become a public health issue in the United States with rising incidence and prevalence, 
escalating costs and increased morbidity and mortality. All current treatments for renal failure involve many losses and 
stressors. Chronic stress may further compromise the already weakened immune system of patients with end stage renal 
disease (ESRD) on hemodialysis. There appear to be correlations between immune functioning, health-related quality of 
life (HRQOL), depression, and time on dialysis, but the nature of such relationships has not been fully explored using 
current methods and a complete panel of cytokine levels.  
 
Psychoneuroimmunology (PNI) is the study of the interaction of the central nervous system (CNS), endocrine system,   
and immune system (Yang & Glaser, 2002).  This multidirectional communication has an impact on the response to 
stressful events. The PNI framework explains the physical and psychobehavioral interactions that affect the immune 
system (McCain, Gray, Walter, & Robins, 2005). For example, behavioral factors are believed to moderate the immune 
system through neuroendocrine system changes. PNI is a comprehensive model incorporating individual, environmental, 
physiological, and spiritual factors that effectively guide this study. No previous studies have been found that use the PNI 
model to investigate relationships among the variables of interest in the ESRD population. The purpose of this study is to 
examine the relationships of perceived stress, depressive symptoms, and immune status to health related quality of life 
(HRQOL) among patients requiring hemodialysis for ESRD. Possible contributing factors to be evaluated include time    
on dialysis and comorbidities. Figure 1 depicts the proposed relationships among the biological and behavioral variables  
as well as proposed cofactors. Fundamentally, we propose that ESRD and chronic hemodialysis are stressful events 
resulting in biological and behavioral interactions, ultimately altering perception of health-related quality of life.  
 
Figure 1. Conceptual Framework 
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VI. SPECIFIC AIMS   
 
 
EXAMINE CORRELATIONS BETWEEN IMMUNE STATUS AS INDICATED BY CYTOKINE LEVELS, PERCEIVED STRESS, 
AND DEPRESSIVE SYMPTOMS WITH HEALTH RELATED QUALITY OF LIFE AMONG 75 INDIVIDUALS ON 
HEMODIALYSIS FOR ESRD. 
 
 
 
  
VII. BACKGROUND AND SIGNIFICANCE 
Include information regarding pre-clinical and early human studies.  Attach appropriate citations. 
 
The patient with renal failure lives with many chronic stressors, both physical and psychosocial. Products of stress such as 
peptides and steroid hormones are metabolized by the kidney, leading to high circulating levels in the patient with renal 
disease, resulting in a biochemically-induced chronic stress response (Cukor et al., 2007). One of the outcomes of chronic 
stress is suppressed cellular immunity (McEwen, 2007). Thus, chronic stress generated by living with a serious illness may 
compromise the immune system. 
 
Sertic et al. (2007) reported that levels of IL-6, IL-8, IL-10, TNFα, IL-1β, and MCP-1 were significantly higher in chronic 
hemodialysis patients compared to healthy control subjects. In dialysis patients elevated proinflammatory cytokine levels, 
particularly IL-6 and C-reactive protein (CRP), have been implicated in vascular disease events and mortality (Cazzavillan, 
et al., 2007; Lentine, Parsonnet, Taylor, Wrone, & Lafayette, 2006), as well as malnutrition (Ibrahim & Salamony, 2008; 
Koo, et al., 2003). Psychological changes, including depression and decreased quality of life, have been connected to 
inflammatory cytokine changes as well (Dervisoglu, Kir, Kalender, Eraldemir, & Caglayan, 2008).  
 
HRQOL remains lower and mortality rates remain higher for patients with ESRD than for the general population. Many 
factors can influence the patient’s quality of life, including clinical aspects of the disease, side effects of the treatment, 
culture, behavior, values, and relationships with others (Kimmel, 2002; Mapes et al., 2004). Ginieri-Coccossis, Theofilou, 
Synodinou, Tomaras, and Soldatos (2009) reported that patients undergoing dialysis for more than 4 years had lower 
quality of life than those who had recently started hemodialysis.  Hemodialysis patients have consistently been shown to 
have a lower quality of life than patients on other forms of renal replacement therapy. 
 
Depression and depressive symptoms are the most common psychological problem reported by hemodialysis patients 
(Lopes et al., 2004).  Depressive symptoms have been linked with various health problems, including cardiovascular 
disease and malnutrition-inflammation complex (Cukor, Cohen, Peterson, & Kimmel, 2007; Ibrahim & Salamony, 2008; 
Koo et al., 2003). Higher levels of anxiety and depressive symptoms have been linked to increased hospitalization and 
mortality in ESRD patients ((Kimmel & Peterson, 2005; Ye et al., 2008).    
 
Stress is the stimulus that precipitates a response in the brain to activate physiological systems in the body.  Stress 
activates the sympathetic-adrenal-medullary (SAM) axis and the hypothalamic-pituitary-adrenal (HPA) axis, releasing 
pituitary and adrenal hormones that have the potential to dysregulate immune function (Glaser & Kiecolt-Glaser, 2005). 
Thus chronic stress generated by living with a serious illness may compromise the immune system. Elevated levels of 
cortisol may dysregulate cytokine mediation of the immune system, resulting in inhibited inflammatory responses 
(McCain et al., 2005). 
 
Possible contributing factors are length of time on dialysis and comorbidities. Researchers have reported conflicting results 
related to correlations between time on dialysis and severity of stress. Yeh and Chou (2007) reported that stress related to 
fluid and food restrictions and role ambiguity declined with time on dialysis, while Logan, Pellatier-Hibbert, and Hodgins 
(2006) reported that time on dialysis didn’t affect appraisal of stressors. Using a grounded theory approach to study the 
experience of renal failure and treatment with hemodialysis, Gregory, Way, Hutchinson, Barrett, and Parfrey (1998) found 
that meanings are constantly being redefined in response to the environment and changing health status, with stressors 
changing over time as well. No clear patterns have been identified, with some patients experiencing periods of varying 
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stress levels.  
 
 
 
Many hemodialysis patients have one or more common comorbidities that add to their illness burden such as diabetes 
mellitus (DM), hypertension (HTN), cardiovascular disease, connective tissue disorders, liver diseases, acquired immune 
deficiency syndrome (AIDS),  and peripheral vascular disease (PVD) (Beddhu et al., 2000; Snaedal et al., 2009). Beddhu 
et al. found strong correlations between comorbidity scores and hospitalization and mortality in a study of patients on 
hemodialysis and peritoneal dialysis. Further, Snaeldal et al. found more inflammatory activity in patients with congestive 
heart failure and peripheral vascular disease. Certainly such comorbidities must be addressed as cofactors affecting PNI-
related associations.  
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VIII. PRELIMINARY PROGRESS/DATA REPORT 
If available. 
 
N/A 
 
 
 
  
IX. RESEARCH METHOD AND DESIGN 
Include a brief description of the project design including the setting in which the research will be conducted and 
procedures.  If applicable, include a description of procedures being performed already for diagnostic or treatment 
purposes. 
 
This study will utilize a cross-sectional design to investigate factors potentially associated with health-related quality of 
life in patients undergoing hemodialysis. The study will be conducted in the Acute Dialysis Unit (ADU) on the fourth floor 
of the Gateway Building at VCUHS and the Renal Advantage, Inc (RAI) dialysis unit at 2521 Mechanicsville Turnpike, 
Richmond, VA 23223, a facility in which VCUHS routinely refers outpatients on dialysis.  
A total of 75 patients who have been diagnosed with end stage renal disease requiring dialysis, and who are over 21 years 
of age, understand and speak English and are competent to consent will be included. Exclusion criteria include active 
infection/febrile illness or AIDS, diagnosis of cancer, currently on immunosuppressive drugs, or having active psychosis. 
Participants will be screened and consented during one of their hemodialysis treatments by the co-investigator and 
assigned a subject code. Variables of interest include cytokine patterns, stress, HRQOL, and depressive symptoms. During 
the next hemodialysis treatment, the co-investigator will collect 2 ml. plasma from the dialysis access device immediately 
prior to initiation of dialysis for the measurement of cytokines. Stress will be measured by the Perceived Stress Scale 
(PSS), a 10-item self-report scale developed to measure “the degree to which situations in one’s life are appraised as 
stressful” (Cohen, Kamarck, & Mermelstein, 1983, p. 385). HRQOL will be measured by the Functional Assessment of 
Cancer Therapy-General (FACT-G) scale developed by Cella et al. (1993). It was initially developed to measure general 
cancer quality of life but has now been expanded into the Functional Assessment of Chronic Illness Therapy (FACIT) 
Measurement System (formerly the FACT System), a collection of questionnaires designed for use with other chronic 
disease populations (www.facit.org).  The FACT-G (Version 4) is a 27-item self-report scale that includes subscales for 
physical, functional, social/family, and emotional well-being. Depressive symptoms will be measured by the Center for 
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Epidemiological Studies-Depression scale (CES-D), a 20-item self-report designed to measure depressive symptoms in the 
past 7 days. The co-investigator will administer the scales during the first hour of the treatment.  
 
 
X.  PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS (If the VCUHS Investigational Drug Pharmacy is not used),   
DEVICES, AND BIOLOGICS  
Describe your plans for the control of investigational products including: (1) how you will maintain records of the 
product’s delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or 
alternative disposition of unused product(s); (2) plan for storing the investigational product(s) as specified by the 
sponsor (if any) and in accordance with applicable regulatory requirements; (3) plan for ensuring that the 
investigational product(s) are used only in accordance with the approved protocol; and (4) how you will ensure that 
each subject understands the correct use of the investigational product(s) (if applicable) and check that each subject 
is following the instructions properly (on an ongoing basis). 
 
N/A 
 
 
 
XI. DATA ANALYSIS PLAN 
For investigator–initiated studies. 
 
Descriptive statistics will be computed for demographic information and clinical factors including body mass index (BMI), 
length of time on dialysis, time since diagnosis of chronic renal failure (CRF), and comorbidities. Regression analysis will 
be used to determine the relationships of perceived stress, depressive symptoms, and immune status to HRQOL. 
  
 
  
XII. DATA AND SAFETY MONITORING 
• If the research involves greater than minimal risk and there is no provision made for data and safety monitoring 
by any sponsor, include a data and safety-monitoring plan that is suitable for the level of risk to be faced by 
subjects and the nature of the research involved.   
• If the research involves greater than minimal risk, and there is a provision made for data and safety monitoring 
by any sponsor, describe the sponsor’s plan. 
• If you are serving as a Sponsor-Investigator, identify the Contract Research Organization (CRO) that you will be 
using and describe the provisions made for data and safety monitoring by the CRO.  Guidance on additional 
requirements for Sponsor-Investigators is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#X-2.htm 
 
This study is non-interventional and involves minimal risk. 
 
 
  
XIII. MULTI-CENTER STUDIES 
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-center project, 
describe the plan for management of information that may be relevant to the protection of subjects, such as 
reporting of unexpected problems, project modifications, and interim results. 
 
N/A 
 
 
 
XIV. INVOLVEMENT OF NON-VCU INSTITUTIONS/SITES (DOMESTIC AND FOREIGN)   
1. Provide the following information for each non-VCU institution/site (domestic and foreign) that has agreed to 
participate: 
• Name of institution/site 
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• Contact information for institution/site 
 
Renal Advantage Inc. 
Dr. Todd Gehr 
 
2.   For each institution, indicate whether or not it is “engaged” in the research (see OHRP’s guidance on 
“Engagement of  
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/assurance/engage.htm.)  
 
 
Not engaged 
 
 
3.   Provide a description of each institution’s role (whether engaged or not) in the human subjects research, 
adequacy of the facility (in order to ensure human subject safety in the case of an unanticipated emergency), 
responsibilities of its agents/employees, and oversight that you will be providing in order to ensure adequate and 
ongoing protection of the human subjects.  You should only identify institutions that have agreed to participate.  If 
additional institutions agree to participate at a later time, they must be added by amendment to the protocol.   
 
 
Renal Advantage, Inc. (RAI) is a chronic dialysis unit that provides routine outpatient hemodialysis to patients with ESRD. 
The staff will be providing the usual care only to patients. Patients are followed by a Nephrologist assigned to them and an 
RN is always assigned to oversee patient care during the treatment. Informed consent, questionnaire data, and blood 
specimens will be obtained by the nurse researcher.    
 
 
4.   For each institution that is “engaged” provide an OHRP Federalwide Assurance (FWA) # if: (1) the research is 
not exempt, AND (2) the research involves a DIRECT FEDERAL award made to VCU (or application for such).  
 
NOTE: Additional guidance at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-6.htm, and 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-11.htm. 
 
N/A 
 
 
 
 
 
XV. INVOLVEMENT OF INDEPENDENT INVESTIGATORS 
 
INDEPENDENT INVESTIGATOR:  an individual who is acting independently and not acting as an agent or employee of 
any institution or facility while carrying out his or her duties in the research protocol. Additional guidance at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-15.htm. 
 
ENGAGEMENT IN RESEARCH:  An independent investigator becomes "engaged" in human subjects research when 
he/she (i) intervenes or interacts with living individuals for research purposes; or (ii) obtains individually 
identifiable private information for research purposes [45 CFR 46.102(d)-(f)]. See OHRP’s guidance on 
“Engagement of Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/assurance/engage.htm. 
 
1.  Provide a list of independent investigators.  
 
 
2.  For each independent investigator indicate whether or not he/she is “engaged” or “not engaged” in the research  
  
3.  For each independent investigator who is “engaged”: (1) describe his/her role with human subjects/identifiable 
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human data, AND (2) describe YOUR oversight of his/her involvement.   
 
N/A 
 
 
 
 
NOTE: If an independent investigator is “engaged,” and the research is (1) not exempt AND (2) involves a DIRECT FEDERAL 
award made to VCU (or application for such), the independent investigator must sign a formal written agreement with 
VCU certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must directly 
supervise all of the research activities, (2) agreement must follow the ORSP template, (3) IRB must agree to the 
involvement of the independent investigator, AND (4) agreement must be in effect prior to final IRB approval.  
 
XVI. HUMAN SUBJECTS INSTRUCTIONS (Be sure to use the sub-headings under A-I) 
ALL sections of the Human Subjects Instructions must be completed with the exception of the section entitled 
“Special Consent Provisions.”  Complete that section if applicable. 
 
A.  DESCRIPTION 
Provide a detailed description of the proposed involvement of human subjects or their private identifiable data in 
the work. 
 
Subjects will be screened and consent obtained during a regularly scheduled dialysis treatment and will participate in the 
study on their next dialysis day. Subjects will be approached after dialysis has been initiated and they are comfortably 
settled into the dialysis treatment. Comorbidities, clinical factors and time on dialysis will be collected from patient 
records. All patients are routinely assessed by the nurse assigned to the patient for physical and mental stability prior to 
each dialysis session. Immediately prior to the start of dialysis 2 ml. of blood will be drawn from the dialysis access. 
Comorbidities to be ascertained include diabetes mellitus (DM), hypertension (HTN), cardiovascular disease, connective 
tissue disorders, liver diseases, hepatitis B virus (HBV) and hepatitis C virus (HCV) and peripheral vascular disease 
(PVD). Subjects will complete the PSS, FACT-G, and CES-D during the first hour of the dialysis treatment. 
 
 
 
B.  SUBJECT POPULATION 
Describe the subject population in terms of sex, race, ethnicity, age, etc., and your access to the population that will 
allow recruitment of the necessary number of participants.  Identify the criteria for inclusion or exclusion of any 
subpopulation and include a justification for any exclusion.  Explain the rationale for the involvement of special 
cases of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to 
be vulnerable.  If you plan to allow for the enrollment of Wards of the State (or any other agency, institution, or 
entity), you must specifically request their inclusion and follow guidance on Wards and Emancipated Minors in the 
VCU IRB Written Policies and Procedures (specifically WPP#: XV-3) available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XV-3.htm.  
 
Patients treated in the Acute Dialysis Unit (ADU) at VCUHS are 93.8% African American with 56.3% male. Most of the 
patients are within the 45-64 year age range with 43.8% aged 45-54 and 31.3% aged 55-64.  
The co-investigator is the Nurse Manager of the ADU and has access to this population. Application to access the patients 
at the Renal Advantage, Inc. (RAI) unit has been obtained and will be completed following IRB approval.   
Patients who have been diagnosed with end stage renal disease requiring dialysis and who are over 21 years of age and 
competent to consent will be included. Patients with active infections or AIDS, diagnosis of cancer, currently on 
immunosuppressive drugs, or who have active psychosis will be excluded.   
 
 
C.  RESEARCH MATERIAL 
Identify the sources of research material obtained from individually identifiable living human subjects in the form 
of specimens, records, or data.  Indicate whether the material or data will be obtained specifically for research 
purposes or whether use will be made of existing specimens, records, or data. 
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Length of time on dialysis, length of time since diagnosis of CRF, clinical data, and comorbidity data will be collected 
from the patient record and used for research purposes only.  Participants will complete self-report instruments (PSS, 
FACT-G, and CES-D) and blood will be collected from the dialysis access for research purposes only. 
All study data will be assigned an arbitrary code number and then all identifying information will be removed from the 
data record and attached to the consent form. Consent forms with identifying information will be filed in an undisclosed 
location under lock and key and available only to the PI and co-investigator Allen.  
 
 
D.  RECRUITMENT PLAN 
Describe in detail your plans for the recruitment of subjects including: (1) how potential subjects will be identified 
(e.g., school personnel, health care professionals, etc), (2) how you will get the names and contact information for 
potential subjects, and (3) who will make initial contact with these individuals (if relevant) and how that contact will 
be done.  If you plan to involve special cases of subjects, such as children, pregnant women, human fetuses, 
neonates, prisoners or others who are likely to be vulnerable, describe any special recruitment procedures for these 
populations. 
 
Co-investigator Avis Allen will identify potential subjects in the ADU at VCUHS and will make the initial contact during 
the routine dialysis treatment, provide the initial screening, and obtain consent.  The charge nurse at the RAI unit will be 
the contact person to identify potential subjects.  Initial contact then will be made by the co-investigator and she will 
provide the initial screening, and obtain consent.  
 
 
 
E.  POTENTIAL RISKS 
Describe potential risks whether physical, psychological, social, legal, or other and assess their likelihood and 
seriousness.  Where appropriate, describe alternative treatments and procedures that might be advantageous to the 
subjects. 
 
No treatments are included in this study. It is possible but very unlikely that the self-report measures may be distressing for 
the subjects. The investigators are highly skilled in potentially emotional interactions. In the event of signs of distress, a 
referral will be made to appropriate health care practitioners. Blood will be drawn but will be limited to a 2 ml. sample 
taken during the routine start of the hemodialysis treatment. No peripheral venipuncture will be required.  
 
 
 
F.  RISK REDUCTION 
Describe the procedures for protecting against or minimizing potential risk.  Where appropriate, discuss provisions 
for ensuring necessary medical or professional intervention in the event of adverse events to the subjects.  Also, 
where appropriate, describe the provisions for monitoring the data collected to ensure the safety of subjects. 
 
All subjects are assessed for orientation and physical ability by a registered nurse experienced in dialysis care prior to each 
treatment as part of their routine care. This assessment will be used to determine their ability to participate in the study.  
Blood samples will be drawn in a sterile manner from the dialysis vascular access by the highly skilled and experienced 
co-investigator. In the event of signs of distress or a score exceeding 16 on the CES-D, a referral will be made to the social 
worker for the dialysis unit. All study data will be de-identified. 
 
 
G.  ADDITIONAL SAFEGUARDS IF ANY PARTICIPANTS WILL BE VULNERABLE  
Describe any additional safeguards to protect the rights and welfare of participants if you plan to involve special 
cases of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to 
be vulnerable.  Safeguards to protect the rights and welfare of participants might relate to Inclusion/Exclusion 
Criteria: (“Adults with moderate to severe cognitive impairment will be excluded.”  “Children must have diabetes.  
No normal controls who are children will be used.”)  Consent: (“Participants must have an adult care giver who 
agrees to the participant taking part in the research and will make sure the participant complies with research 
procedures.”  “Adults must be able to assent.  Any dissent by the participant will end the research procedures.”)  
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Benefit: (“Individuals who have not shown benefit to this type of drug in the past will be excluded.”).   
 
N/A 
 
 
 
 
 
 
H.  CONFIDENTIALITY 
Describe how the confidentiality of data collected as part of this project will be protected including pre-screening 
data (e.g., physical controls on the data; access controls to the data; coding of data; legal controls, such as a Federal 
Certificate of Confidentiality; statistical methods; or reporting methods). 
 
All data will be assigned an arbitrary code number and consent forms with identifying information will be stored in a 
locked file cabinet in an undisclosed location with access only by the PI and co-investigator. The arbitrary codes will be 
verified and kept by the PI throughout the study. Completed paper instruments will be stored in a locked file cabinet in the 
VCU School of Nursing. Data will be entered into a database that is password protected with the password known only to 
the study investigators. Error checks will be routinely done and the database reconciled. No identifying information will be 
entered into the database.  
 
 
 
I.  PRIVACY 
Describe how the privacy interests of subjects will be protected where privacy refers to persons and their interests in 
controlling access to themselves, and assess their likely effectiveness.  Identify what steps you will take for subjects to 
be comfortable: (1) in the research setting and (2) with the information being sought and the way it is sought. 
 
During the data collection, patients will be comfortably seated in the dialysis recliner (RAI unit) or bed (VCUHS Acute 
Unit) during their regular dialysis treatment. They will be receiving their usual care. Care will be taken to ensure that fully 
informed consent is obtained from all subjects. 
 
 
 
J.  RISK/BENEFIT 
Discuss why the risks to subjects are reasonable in relation to the anticipated benefits to subjects and in relation to 
the importance of the knowledge that may reasonably be expected to result.  If a test article (investigational new 
drug, device, or biologic) is involved, name the test article and supply the FDA approval letter. 
 
There are no interventions in this study proposal, thus there is minimal risk and no adverse events are expected.  
Subjects will have no direct benefits except the possible altruistic reward of contributing to research that may have future 
benefits for patients on hemodialysis. 
 
 
 
K. COMPENSATION PLAN 
Compensation for subjects (if applicable) should be described, including possible total compensation, any proposed 
bonus, and any proposed reductions or penalties for not completing the project. 
 
N/A 
 
 
 
L.  CONSENT ISSUES 
 
1.  CONSENT PROCESS 
Indicate who will be asked to provide consent/assent, who will obtain consent/assent, what language (e.g., English, 
Spanish) will be used by those obtaining consent/assent, where and when will consent/assent be obtained, what steps 
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will be taken to minimize the possibility of coercion or undue influence, and how much time will subjects be afforded 
to make a decision to participate. 
 
Patients receiving hemodialysis at the ADU and RAI unit will be screened and consent will be obtained by co-investigator 
Avis Allen, Nurse Manager of the ADU. Consent will be in English and will be obtained at the ADU and RAI unit during 
the patient’s scheduled dialysis visit. Subjects will be informed that agreeing or declining to participate will not affect their 
care, and they will have 48 hours to discuss their participation with family members or significant others prior to study 
participation. 
 
2.  SPECIAL CONSENT PROVISIONS 
If some or all subjects will be cognitively impaired, or have language/hearing difficulties, describe how capacity for 
consent will be determined. Please consider using the VCU Informed Consent Evaluation Instrument available at 
http://www.research.vcu.edu/irb/guidance.htm.  If you anticipate the need to obtain informed consent from legally 
authorized representatives (LARs), please describe how you will identify an appropriate representative and ensure 
that their consent is obtained.  Guidance on LAR is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-3.htm.  
 
Patients with cognitive impairment or who do not speak English will not be eligible to participate. 
 
 
 
3.  If request is being made to WAIVE SOME OR ALL ELEMENTS OF INFORMED CONSENT FROM SUBJECTS OR 
PERMISSION FROM PARENTS, explain why: (1) the research involves no more than minimal risk to the subjects, (2) the 
waiver or alteration will not adversely affect the rights and welfare of the subjects, (3) the research could not 
practicably be carried out without the waiver or alteration; AND (4) whether or not subjects will be debriefed after 
their participation.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-1.htm..  
NOTE: Waiver is not allowed for FDA-regulated research unless it meets FDA requirements for Waiver of Consent 
for Emergency Research (see below). 
 
N/A 
 
 
 
4.  If request is being made to WAIVE DOCUMENTATION OF CONSENT, provide a justification for waiver based on one 
of the following two elements AND include a description of the information that will be provided to participants: (1) 
the only record linking the subject and the research would be the consent document and the principal risk would be 
potential harm resulting from a breach of confidentiality.  Subject will be asked whether they want documentation 
linking them with the research, and each subject’s wishes will govern; or (2) the research presents no more than 
minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside 
of the research context.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-
2.htm 
 
N/A 
 
 
 
5.  If applicable, explain the ASSENT PROCESS for children or decisionally impaired subjects.  Describe the 
procedures, if any, for re-consenting children upon attainment of adulthood. Describe procedures, if any, for 
consenting subjects who are no longer decisionally impaired.  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XV-2.htm.and 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-7.htm. 
 
N/A 
 
 
 
6.  If request is being made to WAIVE THE REQUIREMENT TO OBTAIN ASSENT from children  age 7 or higher, or 
decisionally impaired subjects, explain why: (1) why some or all of the individuals  age 7 or higher will not be 
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capable of providing assent based on their developmental status or impact of illness; (2) the research holds out a 
prospect of direct benefit not available outside of the research; AND/OR (3) [a] the research involves no more than 
minimal risk to the subjects, [b] the waiver or alteration will not adversely affect the rights and welfare of the 
subjects, [c] the research could not practicably be carried out without the waiver or alteration; AND [d] whether or 
not subjects will be debriefed after their participation.  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XV-2.htm   
 
N/A 
 
 
7. If request is being made to waive consent for emergency research, see guidance at 
http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XVII-16.htm. 
 
N/A 
 
 
 
8.  If applicable, address the following issues related to GENETIC TESTING: 
 
a. FUTURE CONTACT CONCERNING FURTHER GENETIC TESTING RESEARCH 
Describe the circumstances under which the subject might be contacted in the future concerning further 
participation in this or related genetic testing research. 
 
N/A 
 
 
 
b. FUTURE CONTACT CONCERNING GENETIC TESTING RESULTS 
If planned or possible future genetic testing results are unlikely to have clinical implications, then a statement that 
the results will not be made available to subjects may be appropriate. If results might be of clinical significance, then 
describe the circumstances and procedures by which subjects would receive results. Describe how subjects might 
access genetic counseling for assistance in understanding the implications of genetic testing results, and whether this 
might involve costs to subjects. Investigators should be aware that federal regulations, in general, require that 
testing results used in clinical management must have been obtained in a CLIA-certified laboratory. 
 
N/A 
 
 
 
c. WITHDRAWAL OF GENETIC TESTING CONSENT 
Describe whether and how subjects might, in the future, request to have test results and/or samples withdrawn in 
order to prevent further analysis, reporting, and/or testing. 
 
N/A 
 
 
d. GENETIC TESTING INVOLVING CHILDREN OR DECISIONALLY IMPAIRED SUBJECTS 
Describe procedures, if any, for consenting children upon the attainment of adulthood. Describe procedures, if any, 
for consenting subjects who are no longer decisionally impaired. 
 
N/A 
 
 
e. CONFIDENTIALITY 
Describe the extent to which genetic testing results will remain confidential and special precautions, if any, to protect 
confidentiality. 
N/A 
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BIOBEHAVIORAL RELATIONSHIPS IN PERSONS ON HEMODIALYSIS 
SCREENING FORM Date: _______________ 
1. Age 21 or older 
a. Yes 
b. No 
 
2. Understand and speak English 
a. Yes 
b. No 
 
3. Capable of giving informed consent 
a. Yes 
b. No 
 
4. Acute infection/febrile illness 
a. Yes 
b. No 
 
5. HIV infection 
a. Yes 
b. No 
 
6. Cancer diagnosis and/or treatment within 5 years (exclusion of non-melanoma skin cancer within last 6 
months) 
 
a. Yes 
b. No 
 
7. Taking  immunosuppressive medications currently or within the past month 
a. Yes 
b. No 
 
8. Diagnosis of psychotic disorder 
a. Yes 
b. No 
9. Transplant status 
a. Currently on transplant list 
b. Not on transplant list 
c. Prior transplant 
SCREENED IN: ______NO ______YES     ID#_________________  
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BIOBEHAVIORAL RELATIONSHIPS IN PERSONS ON HEMODIALYSIS   ID# 
McCain/Allen                                                                   
Demographic Form                                                                    Date:                 /            /                     
  
1. Participant’s date of birth:    
         m   m      d    d       y    y 
2. What is your ethnicity?   
 Hispanic or Latino    
 Not-hispanic or Latino  
3. What is your race? 
 American Indian/Alaska Native  
 Asian  
 Black or African-American  
 Native Hawaiian or Other Pacific Islander  
 White  
 More than one race  
 
4.  Time on dialysis:              
                                     Yr.        Mo. 
 
5.   Date of first dialysis treatment:   
 m  m        d   d       y   y 
 
6.   Last KT/V:   
 
7. BMI:   
 
8.  Dialysis access: 
   
        
   
 
9.  Comorbidities: 
   
   
   
   
                      Peripheral Vascular Disease 
Connective Tissue Disorder 
Cardiovascular Disease 
Hypertension 
Liver Diseases Diabetes Mellitus 
Catheter 
Graft 
Fistula 
Hepatitis C 
Hepatitis B 
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10. Smoking history: 
Do you smoke? 
  No  
  Yes  
 How long has it been since you quit smoking  
(please indicate days, months or years)?                         __________ 
Not applicable                  
 How many packs do you smoke per day? 
  Not applicable  
11. Do you drink alcohol?  
 No   
 Yes  
If yes, how much? 
12. Do you use recreational drugs (such as marijuana, prescription drugs for relaxation)?  
 No   
 Yes  
If yes, how much/how often?___________________________________ 
Which substances?___________________________________________ 
13. Do you use prescription medications? 
 No  
 Yes_________________________________________________________  
14. Do you use over-the-counter (OTC) medications? 
 No  
 Yes (please check all that apply)  
  Vitamins  
  Supplements  
  Other (please list)____________________________________________  
15. What is your highest level of education? 
 Started high school  
 Completed high school  
 Started technical training  
 Completed technical training  
 Started college  
 Completed college  
 Started post-college  Completed post-college  
 
16. Blood pressure:                     /                   Pulse 
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BIOBEHAVIORAL RELATIONSHIPS IN PERSONS ON HEMODIALYSIS 
McCain/Allen 
Perceived Stress Scale 
Directions : The questions below ask you about your feelings and thoughts  during the 
LAST MONTH .  Please fill in the corresponding bubble that best describes  how 
often  you felt or thought like the statement.  There is no right or wrong answer. 
Never 
  Almost 
   never Sometimes 
  Very 
  often 
1.  Been upset because of something that 
     happened unexpectedly. 
   Fairly 
   often 
In the last MONTH, how often have you... 
2.  Felt that you were unable to control 
     the important things in your life. 
3.  Felt nervous and "stressed". 
4.  Felt confident about your ability to 
     handle your personal problems. 
5.  Felt that things were going your way. 
6.  Found that you could not cope with all 
     the things that you had to do. 
7.  Been able to control irritations in your life. 
8.  Felt that you were on top of things. 
9.  Been  angered because of things that 
     happened that  were outside of your 
     control. 
Subject ID 
Date / / 
10.  Felt difficulties were piling up so high 
      that you could not overcome them. 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
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BIOBEHAVIORAL RELATIONSHIPS IN PERSONS ON HEMODIALYSIS 
McCain/Allen 
CES-D 
Directions: Below are feelings some people have.  Please fill in the corresponding bubble that best fits  
how much you have had each feeling during the past week .  If you have not had this feeling at all then fill in the 
bubble for "less than one day each week or none".  There are no right or wrong answers. 
Less than 1 day 
each week or none 
  1-2 days 
 per week 
  3-4 days 
 per week 
Most  of 
the time 
1.  I was bothered by things that 
     usually don't bother me. 
0 1 2 3 
2.  I did not feel like eating; my 
     appetite was poor. 
0 1 2 3 
3.  I felt that I could not shake 
     off the blues even with help 
     from my family or friends. 
0 1 2 3 
4.  I felt that I was just as good 
     as other people. 
0 1 2 3 
5.  I had trouble keeping my 
     mind on what I was doing. 
0 1 2 3 
6.  I felt depressed. 0 1 2 3 
7.  I felt that everything I did 
      was an effort. 
0 1 2 3 
8.  I felt hopeful about the future. 0 1 2 3 
9.  I thought my life had been a 
     failure. 
0 1 2 3 
10.  I felt fearful. 0 1 2 3 
11. My sleep was restless. 0 1 2 3 
12.  I was happy. 0 1 2 3 
13.  I talked less than usual. 0 1 2 3 
Subject ID 
Date / / 
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Less than 1 day
each week or none
  1-2 days
 per week
  3-4 days
 per week
Most  of
the time
14.  I felt lonely. 0 1 2 3
15.  People were unfriendly. 0 1 2 3
16.  I enjoyed life. 0 1 2 3
17.  I had crying spells. 0 1 2 3
18.  I felt sad. 0 1 2 3
19.  I felt that people disliked me. 0 1 2 3
20.  I could not get "going". 0 1 2 3  
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BIOBEHAVIORAL RELATIONSHIPS IN PERSONS ON HEMODIALYSIS 
McCain/Allen 
FACT-G (Version 4) 
Below is a list of statements that other people with your illness have said are 
important.  By filling in one (1) circle per line, please indicate how true each 
statement has been for you  during the past 7 days . 
PHYSICAL WELL-BEING 
GP1 
GP2 
GP3 
GP4 
GP5 
GP6 
GP7 
I have lack of energy................................................................. 
I have nausea............................................................................. 
Because of my physical condition, I have trouble meeting the 
needs of my family........................................................................ 
I have pain.................................................................................... 
I feel ill......................................................................................... 
I am forced to spend time in bed................................................... 
I am bothered by side effects of treatment..................................... 
SOCIAL/FAMILY WELL-BEING 
GS1 
GS2 
GS3 
GS4 
GS5 
GS6 
GS7 
I feel close to my friends......................................................... 
I get emotional support from my family.................................. 
I get support from my friends.................................................. 
My family has accepted my illness........................................... 
I feel close to my partner (or the person who is my main 
support)............................................................... 
I am satisfied with my sex life................................................. 
I am satisfied with family communication about my illness.... 
0 1 2 3 4 
  Not at 
     all 
   A 
 little 
  bit 
  Some 
  what 
Quite 
 a bit 
Very 
much 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
 Q1 Regardless of your current level of sexual activity, please answer the following question. 
If you prefer not to answer, please check this box         and go to the next section. 
0 1 2 3 4 
   Not at 
      all 
   A 
 little 
  bit 
 Some 
  what 
Quite 
 a bit 
Very 
much 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
Subject ID 
Date / / 
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EMOTIONAL WELL-BEING
GE1
GE2
GE3
GE4
GE5
GE6
I feel sad...................................................................................
I am satisfied with how I am coping with my illness................
I am losing hope in the fight against my illness..........................
I feel nervous...............................................................................
I worry that my condition will get worse......................................
I worry about dying.......................................................................
FUNCTIONAL WELL-BEING
GF1
GF2
GF3
GF4
GF5
GF6
GF7
I am able to work (include work at home).............................
My work (include work at home) is fulfilling........................
I am able to enjoy life.............................................................
I have accepted my illness.....................................................
I am enjoying the things I usually do for fun.........................
I am content with the quality of my life right now................
I am sleeping well..................................................................
0 1 2 3 4
   Not at
      all
   A
 little
  bit
  Some
  what
Quite
 a bit
Very
much
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
   Not at
     all
   A
 little
  bit
 Some
  what
Quite
 a bit
Very
much
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
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CHAPTER 4:  Biobehavioral Relationships and Health Related Quality of Life in  
Persons with End Stage Renal Disease on Hemodialysis  
Abstract 
 Health-related quality of life (HRQOL) is lower and mortality rates are higher for 
patients with end stage renal disease (ESRD) than for the general population. However, the 
relationships among perceived stress, immune functioning, depression, disease-related factors, 
and health-related quality of life have not been fully explored in this population. The purpose of 
this study was to examine the relationships among perceived stress, immune indicators, 
depressive symptoms, disease-related factors and HRQOL among patients requiring 
hemodialysis for ESRD.  
 The sample included 75 adults with ESRD requiring dialysis who consented and were 
enrolled in the study.  Exclusion criteria included acute infections, human immunodeficiency 
virus infection (HIV), cancer, current use of immunosuppressive drugs, or active psychosis. 
Blood for cytokine analyses was drawn from the dialysis access port immediately prior to the 
start of dialysis. Participants completed a demographic questionnaire and the three psychosocial 
measures: the Perceived Stress Scale (PSS), the Center for Epidemiologic Studies Depression 
Scale (CES-D), and a quality of life measure, the Functional Assessment of Cancer Therapy-
General scale (FACT-G),  during the first hour of the dialysis treatment. 
The sample was predominantly African American (75.7%) and male (65%) with a mean 
age of 53.9 years (range 23-83). Mean time that participants had been on dialysis was 3.0 years 
with a range of less than 1 month to 20.8 years. Most participants had been diagnosed with 
hypertension (85%) and diabetes (59%). Mean levels of perceived stress were 15.9 (SD = 8.0), 
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levels of depressive symptoms were 16.2 (SD = 12.7), and levels of HRQOL were 68.1 (SD = 
14.2). Multiple regression models were constructed with log-transformed cytokine data.  
Negative correlations were found between perceived stress and HRQOL (p = 0.0240-0.0287) and 
depressive symptoms with health-related quality of life (p = 0.0007-<.0001). MIP-1 ß was the 
only cytokine significantly (and positively) correlated with HRQOL ( p =  0.0034-0.0068).  
Principal component analysis of the cytokine data revealed three factors: Factors 1 and 3 
represented a pro-inflammatory cytokines and Factor 2 represented a mixture of pro-
inflammatory and anti-inflammatory cytokines. There was a significant correlation between 
Factor 1 and depressive symptoms (p = 0.0069). Significant differences in the distributions of 
Factors 2 and 3 were associated with the presence of cardiovascular disease (Chi-square = 4.0, df 
= 1, p = 0.047), (Chi-square = 4.1, df = 1, p = 0.043), respectively, and Factor 3 with 
hypertension (Chi-square = 7.6. df = 1, p = 0.006). However, no relationships were found 
between the cytokine factors and HRQOL, PSS, or other variables. Findings suggest that there 
are relationships among psychosocial variables and possibly biological interactions that may 
affect perceptions of HRQOL among persons with ESRD on hemodialysis. 
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Biobehavioral Relationships and Health Related Quality of Life in  
Persons with End Stage Renal Disease on Hemodialysis  
Over 350,000 persons in the United States with End Stage Renal Disease (ESRD) must 
have thrice weekly in-center hemodialysis sessions to maintain their kidney function.  In-center 
dialysis is time intensive and physically and financially burdensome to ESRD patients. In 
addition to dialysis, patients with  ESRD live with changes in diet, fluid restrictions, weakness 
and pain, loss of income, perceptions of stress, and role changes within the family (Kimmel, 
2002; Kring & Crane, 2009; Mapes et al., 2004). Hence, it is not surprising that hemodialysis 
patients have consistently been shown to have a lower quality of life than patients on other forms 
of renal replacement therapy. Decreased quality of life in dialysis patients has been shown to be 
linked with increased risk of death (Mapes et al., 2004). However, little research has examined 
the relationships of psychosocial and immune measures that may be associated with health 
related quality of life (HRQOL) in persons with ESRD on hemodialysis.  
The psychoneuroimmunolgy (PNI) model provides an appropriate framework for the 
examination of the biological and behavioral factors affecting HRQOL in persons with ESRD on 
hemodialysis. PNI is the study of the interaction of the central nervous system (CNS), endocrine 
system, and immune system (Yang & Glaser, 2002).  This multidirectional communication has 
an impact on the response to stressful events. The PNI framework explains the physical and 
psychosocial interactions related to stress that affect the immune system (McCain, Gray, Walter, 
& Robins, 2005). Psychosocial and behavioral factors are believed to moderate the immune 
system through neuroendocrine system changes. Psychosocial variables of interest in this study 
included perceived stress, depressive symptoms, and HRQOL. Disease-related factors included 
comorbidities, time on dialysis, and medications. No previous studies are known to have used the 
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PNI model to investigate relationships among these variables in the ESRD population. 
Fundamentally, we propose that hemodialysis for ESRD is stressful, resulting in biological and 
behavioral interactions, ultimately affecting perceptions of health-related quality of life. Figure 1 
depicts the proposed relationships among the variables in this study. Stress and depressive 
symptoms are key moderating variables in this PNI-based model. 
Figure 1. Relationships among Study Variables  
 
 
Stress 
Stress is the stimulus that precipitates a response in the brain to activate physiological 
adaptive systems.  The sympathetic-adrenal-medullary (SAM) axis and the hypothalamic-
pituitary-adrenal (HPA) axis are activated, releasing pituitary and adrenal hormones that have the 
potential to dysregulate immune function (Glaser & Kiecolt-Glaser, 2005). Products of stress 
such as peptides and steroid hormones are metabolized by the kidney, leading to high circulating 
levels in the patient with renal disease, resulting in a biochemically-induced chronic stress 
response (Cukor et al., 2007). One of the outcomes of chronic stress is suppressed cellular 
immunity (McEwen, 2007). Thus, chronic stress generated by living with a serious illness such 
as renal failure may further compromise the immune system in patients with ESRD. Stress has 
also been associated with both depression and decreased quality of life. 
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Depression 
Depression is the most common psychological problem reported by hemodialysis patients 
(Lopes et al., 2004) and has been associated with decreased quality of life (Dogan, Eryonucu, 
Sayarlioglu & Agargun, (2005).  Depression has been linked with various health problems, 
including cardiovascular disease and malnutrition-inflammation complex (Cukor, Cohen, 
Peterson, & Kimmel, 2007; Ibrahim & Salamony, 2008; Koo et al., 2003). Lopes et al. (2004) 
used the short version of the Center for Epidemiological Studies-Depression Scale (CES-D) to 
assess depressive symptoms in hemodialysis patients and found that 48% of dialysis patients had 
a score >10, indicating probable depression (Lopes et al., 2004). Higher levels of anxiety and 
depression have been linked to increased hospitalization and mortality in ESRD patients 
(Kimmel & Peterson, 2005; Ye et al., 2008). Depression has also been linked to changes in 
immune function in the general population as well as patients on hemodialysis for ESRD (Hung 
et al., 2011; Ranjit et al., 2007).    
Immune Factors  
Immune factors such as cytokines may be associated with increased cardiovascular 
disease, malnutrition, and decreased quality of life in patients on hemodialysis. Sertic et al. 
(2007) reported that levels of interleukin (IL)-6, IL-8, IL-4, IL-10, tumor necrosis factor-alpha 
(TNF-α), IL-1α, IL-1β, and monocyte chemotactic protein-1 (MCP-1) were significantly higher 
in chronic hemodialysis patients compared to healthy control subjects. In dialysis patients 
elevated pro-inflammatory cytokine levels, particularly IL-6, and C-reactive protein (CRP) have 
been implicated in vascular disease events and mortality (Cazzavillan, et al., 2007; Lentine, 
Parsonnet, Taylor, Wrone, & Lafayette, 2006) as well as malnutrition (Ibrahim & Salamony, 
2008; Koo et al., 2003). Psychological changes, including depression and decreased quality of 
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life, have been associated with inflammatory cytokine changes as well (Dervisoglu, Kir, 
Kalender, Eraldemir, & Caglayan, 2008). Many common comorbidities associated with ESRD, 
such as diabetes and hypertension have also been implicated in immune status changes. 
Disease-related Factors 
Disease-related factors may add to the burden of living with ESRD. Many hemodialysis 
patients have one or more common comorbidities that add to their illness burden, including 
diabetes mellitus (DM), hypertension (HTN), cardiovascular disease (CVD), connective tissue 
disorders, liver diseases (including hepatitis B and C), acquired immune deficiency syndrome 
(AIDS),  and peripheral vascular disease (PVD) (Beddhu et al., 2000; Snaedal et al., 2009). 
Reflecting the ongoing burden of hemodialysis, one study found that patients undergoing 
hemodialysis for more than four years had lower quality of life than those who had recently 
started hemodialysis (Ginieri-Coccossis, Theofilou, Synodinou, Tomaras, and Soldatos, 2009).  
Beddhu et al. (2000) found strong correlations between comorbidity scores and hospitalization 
and mortality in a study of patients on hemodialysis and peritoneal dialysis. Further, Snaeldal et 
al. (2009) found associations between inflammatory activity and congestive heart failure and 
peripheral vascular disease. Certainly such comorbidities must be considered as critical cofactors 
in a PNI-framework when examining factors related to HRQOL.  
Treatment for ESRD is experienced through the filter of psychosocial and disease-related 
factors, influencing and interacting with the immune response. This interaction ultimately affects 
HRQOL.  Multiple studies have investigated the association between select variables and 
HRQOL (e.g., Dervisoglu, Kir, Kalender, Eraldemir, & Caglayan, 2008; Dogan, Eryonucu, 
Sayarlioglu, & Agargun, 2005; Tossani, Cassano, & Fava, 2005), but no known studies have 
explored correlations among all of the variables and HRQOL using a PNI model.  Therefore, the 
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purpose of this study was to examine the relationships among disease-related factors, perceived 
stress, depressive symptoms, immune indicators, and HRQOL among patients requiring 
hemodialysis for ESRD using a PNI-based framework. 
Methods 
Participants, Procedures and Setting 
 Participants were recruited from a two sites: a community dialysis unit and a hospital-
based dialysis unit in an urban city in the Southeast. The study was approved by the Institutional 
Review Board of the university and the Research Board of the chronic dialysis facility. Informed 
consent was obtained from all participants. All patients 21 years of age or older diagnosed with 
ESRD requiring dialysis and competent to consent were eligible for inclusion. Exclusion criteria 
included acute infections or AIDS, diagnosis of cancer, currently on immunosuppressive drugs, 
or diagnosed with active psychosis. Potential participants were identified by the charge nurses in 
the dialysis units and then screened and consented by the investigator during a regular dialysis 
treatment session. Data on comorbidities, pertinent clinical factors (such as medications), and 
time on dialysis were collected from patient records. Immediately prior to the start of dialysis, 2 
ml of blood for cytokine analysis was drawn from the dialysis access. Participants completed a 
demographic questionnaire and the three psychosocial measures (Perceived Stress Scale, 
Functional Assessment of Cancer Therapy-General, and Center for Epidemiological Studies-
Depression scale) during the first hour of the dialysis treatment. 
Measures 
Cytokines. Plasma levels of 17 cytokines were measured using a Bio-Plex® multiplex 
suspension array system with BioRad Human 17-Plex® magnetic bead array kits.  The cytokines 
included in the array were IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, 
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granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating 
factor (GM-CSF), interferon-gamma (IFN-γ), monocyte chemotactic protein-1 (MCP-1), 
macrophage inflammatory protein-1 beta (MIP-1ß), and TNF-α. This panel measures analyte 
values in the range of 1.4 ≈ 95,000 pg/ml, with high precision (intra-assay CV 5%-15%, inter-
assay CV 5%-11%, observed vs. expected R2 >0.95) and sensitivity (limit of detection = 0.6-6.4 
pg/ml)(Bio-Plex Pro Tech Note 5803, 2009). 
Psychosocial Measures. Psychosocial variables measured in this study were perceived 
stress, depressive symptoms, and HRQOL. Perceived stress was measured by the Perceived 
Stress Scale (PSS), a 10-item self-report scale developed to measure “the degree to which 
situations in one’s life are appraised as stressful” (Cohen, Kamarck, & Mermelstein, 1983, p. 
385). Questions are designed to capture the extent to which respondents feel their lives are 
unpredictable, uncontrollable, and overloading. The 10 items are rated on a 5-point Likert scale, 
from 0 for never to 4 for very often. A higher score indicates higher levels of perceived stress. 
Chronbach’s alpha was reported to be 0.84-0.86 from a large sample of the general population 
(Cohen et al., 1983). Schwarz and Dunphy (2003) reported a Chronbach’s alpha of 0.87 in a 
study of perceived stress in caregivers of family members with heart failure.     
Depressive symptoms were measured by the Center for Epidemiological Studies-
Depression scale (CES-D), a 20-item self-report designed to measure depressive symptoms in 
the past 7 days. Items are scored from 0 to 3 points with higher scores indicating greater 
depressive symptoms. The CES-D has been found to be a valid and reliable instrument for 
assessing depressive symptoms in the general population with estimates of internal consistency 
ranging from 0.84-0.90 (Radloff, 1977).  
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Health related quality of life was measured by the Functional Assessment of Cancer 
Therapy-General (FACT-G) scale developed by Cella et al. (1993). It was initially developed to 
measure quality of life in persons with cancer but has now been expanded into the Functional 
Assessment of Chronic Illness Therapy (FACIT) Measurement System (formerly the FACT 
System), a collection of questionnaires designed for use with other chronic disease populations 
(www.facit.org).  The FACT-G (Version 4) is a 27-item self-report scale that includes subscales 
for physical, functional, social/family, and emotional well-being. Participants are asked to 
respond to statements as they apply in the last 7 days. Item scores range from 0 (not at all) to 4 
(very much) with higher scale scores indicating better function. Internal consistency coefficients 
range from 0.63 to 0.89 for the subscales and 0.89 for the total score (Webster, Odom, Peterman, 
Lent, & Cella, 1999).   
Biological and Disease-related Factors. Data on comorbidities including diabetes 
mellitus, hypertension, cardiovascular disease,, connective tissue disorders, liver diseases 
(including hepatitis B and C), and peripheral vascular disease were obtained from medical record 
review. Medication profiles were also retrieved from the medical record. Time on dialysis was 
measured from the ESRD Medical Evidence Report, a form completed by the nephrologist for 
Medicare entitlement reports. 
 Analytic Approaches 
JMP® 9.0.0 (SAS Institute, Inc., Cary, NC) was used for statistical analysis. Descriptive 
statistics were computed for demographic information, length of time on dialysis, and 
comorbidities. Chronbach’s alpha was calculated for the PSS, FACT-G, and CES-D. Cytokine 
data were logarithmically transformed because the original data were strongly skewed, then 
descriptive statistics were computed on the log-transformed data.  The log-transformed cytokine 
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data were subjected to factor analysis and principal component analysis. Then relationships 
between the identified components and HRQOL were examined. Multiple regression models 
were constructed to examine the relationships of time on dialysis, cytokines, comorbidities, 
perceived stress, and depressive symptoms with HRQOL. Statistical significance was set at alpha 
= 0.05. Each participant was assigned an arbitrary code number and no identifying information 
was entered into the database. Data were entered into a database that was password protected 
with the password known only to the study investigators. Error checks were routinely done and 
the database reconciled.  
Results 
Seventy-five participants were enrolled in the study. A total of 134 candidates were 
screened, 36 were excluded and 23 declined to participate. Exclusions were predominantly due 
to acute infections or current steroid treatment. The sample was predominantly Black (75.7%) 
and male (65%) with a mean age of 53.9 (range 23-83) and over half (65%) had started or 
completed high school. Mean time on dialysis was 3.0 years with a range of less than 1 month to 
over 20 years (20.8) years. Most participants also had been diagnosed with hypertension (85%) 
and diabetes (59%). A majority of participants were taking anti-hypertensive medications 
(78.4%), erythropoietin stimulating hormone drugs (71.6%), iron (51.4%), and/or cardiovascular 
drugs (47.3%).  The sample is similar in age and comorbidities to the national demographics for 
ESRD patients on hemodialysis, but the proportion of African Americans and males in this study 
sample was much higher than the national average (USRDS, 2009). The mean for the PSS was 
15.9 (SD = 8.0), indicating a moderate level of stress in the sample (Cohen & Williamson, 1988). 
The mean for the CES-D was 16.2 (SD = 12.7), indicating a relatively high level of depressive 
symptoms overall (Radloff, 1977). The mean for the FACT-G was 68.1 (SD = 14.2), lower than 
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the mean of 80.1 found in normative studies (Webster, Cella, & Yost, 2003). Means on the 
FACT-G subscales also were below normative data (Webster, Cella, & Yost, 2003), with the 
exception of the Social/Family Well-being subscale. The Physical Well-Being subscale mean 
was 18.7 (normative mean = 22.7), 20.1 (normative mean = 19.1) for the Social/Family Well-
Being subscale, 14.9 (normative mean =19.9) for the Emotional Well-Being subscale, and 14.4 
(normative mean = 18.5) for the Functional Well-Being subscale. Table 1 displays the means for 
the psychosocial data. All three psychosocial measures showed good reliability in this study, 
with a Chronbach’s alpha for the PSS of 0.83, 0.90 for the CES-D, and 0.89 for the FACT-G.  
Table 1. Sample Scores and Normative Data for Psychosocial Measures 
Measure Sample Mean (SD) Normative Mean (SD) 
PSS 15.9 (8.0) 13.0 (6.5) 
CES-D 16.2 (12.7) ---- 
FACT-G 68.1 (14.2) 80.1 (18.1) 
Physical Well-being 18.7 (6.02) 22.7 (5.4) 
Social/Family Well-being 20.1 (6.40) 19.1 (6.8) 
Emotional Well-being 14.9 (3.12) 19.9 (4.8) 
Functional Well-being 14.4 (6.33) 18.5 (6.8) 
 
Actual distributions of the non-transformed cytokine levels are reported in Table 2 in 
pg/ml as measured by the BioRad 17-plex. Medians for the cytokine levels ranged from 0.1 
pg/ml for IL-2 and IL-17 to 153.6 pg/ml for MIP-1β, and standard deviations ranged from 8.09 
pg/ml for IL-4 to 592.11 pg/ml for TNF-α. The cytokine data were not normally distributed and 
therefore were log-transformed for subsequent analyses. Each cytokine was first examined in a 
regression model using only PSS and CES-D as covariates. However the cytokines, with the 
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exception of MIP-1β, were not significantly related to HRQOL. In order to determine if there 
were cytokine patterns that might correlate with HRQOL, a principal component analysis of the 
cytokines was completed, with a varimax rotation to maintain independence of the factors. 
. 
Table 2. Cytokine Levels (pg/ml) 
Cytokine Mean Median SD 
IL-1β 3.80 1.09 17.67 
IL-2 31.63 0.1 191.58 
IL-4 2.68 0.94 8.09 
IL-5 9.77 1.91 54.36 
IL-6 39.71 8.75 149.46 
IL-7 17.81 5.68 59.06 
IL-8 28.42 19.84 29.08 
IL-10 34.34 1.71 220.20 
IL-12 40.21 2.88 204.47 
IL-13 9.21 0.52 37.84 
IL-17 39.37 0.1 201.16 
G-CSF 85.62 48.06 99.14 
GM-CSF 149.38 83.05 383.80 
IFN-γ 181.49 41.56 84.62 
MCP-1 95.11 81.93 70.67 
MIP-1β 168.56 153.59 67.69 
TNF-α 87.37 8.79 592.11 
 
The principal component analysis of cytokine data revealed three factors (Table 3). 
Inspection of the screeplot (Figure 2) revealed a break after the third factor and the three 
components explaining 63% of the variance were retained for further analysis. The first factor 
represented a primarily pro-inflammatory response (IL-1β, IFN-γ, TNF-α, IL-4, and G-CSF) and 
accounted for 32% of variance. The second factor represented a balance of pro-inflammatory and 
anti-inflammatory cytokines (IL-2, IL-7, IL-10, IL-12, IL-13, and IL-17) and accounted for 23% 
of variance. The third factor also represented a pro-inflammatory response (IL-2, IL-6, IL-8, 
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MCP-1, and MIP-1β) and accounted for 17% of variance. Correlations were found between 
immune factor patterns and hypertension and cardiovascular disease. Stenvinkel et al. (1999) and 
Lentine, Parsonnet, Taylor, Wron, and Lafayette (2006) reported similar correlations between 
markers for inflammation and atherosclerotic vascular disease in ESRD.  There were significant, 
albeit low, correlations between Factor 1 and depressive symptoms (r = 0.1, p = 0.01) and 
significant differences in the distributions on Factor 2 by the presence of CVD (Chi-square = 4.0, 
df = 1, p = 0.047), Factor 3 and CVD (Chi-square = 4.1, df = 1, p = 0.043),  and Factor 3 and 
HTN (Chi-square = 7.6. df = 1,  p = 0.006). However, no relationships were found between the 
cytokine factors and other disease-related factors (connective tissue disorder, liver disease, 
and/or peripheral vascular disease), perceived stress, or HRQOL. 
Table 3. Factor Loadings for Log-transformed Cytokine Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine Factor 1 Factor 2 Factor 3 
IL-1β 0.82 0.22 0.17 
IL-2 0.14 0.56 0.54 
IL-4 0.92 0.20 0.10 
IL-5 0.45 0.72 <0 
IL-6 0.45 0.17 0.64 
IL-7 0.39 0.75 -0.20 
IL-8 0.14 0.06 0.72 
IL-10 0.12 0.68 0.32 
IL-12 0.29 0.77 0.23 
IL-13 0.19 0.61 0.45 
IL-17 0.23 0.56 0.47 
G-CSF 0.55 0.27 -0.20 
GM-CSF 0.20 0.17 -0.10 
IFN-γ 0.84 0.25 0.32 
MCP-1 0.12 0.06 0.75 
MIP-1β -0.10 0.10 0.53 
TNF-α 0.75 0.42 0.15 
76 
 
Figure 2. Scree Plot for Cytokine Factors 
 
Multiple regression models were constructed with log-transformed cytokine data (Table 
4). Model 1 included covariates of time on dialysis, diabetes, hypertension, perceived stress, 
depressive symptoms, and cytokine Factors 1, 2, and 3. After controlling for time on dialysis and 
the comorbidities of diabetes, hypertension and cardiovascular disease, HRQOL was found to be 
significantly related with perceived stress (p = 0.0264) and depressive symptoms (p = 0.0007). 
Average HRQOL increased with increased perceived stress and depressive symptoms. In 
regression models with individual cytokines, MIP-1β was found to be the only cytokine 
significantly related with HRQOL. Since MIP-1β  loaded onto Factor 3 in the principal 
component analysis, an alternate model was constructed to include this individual cytokine rather 
than Factor 3.  
Model 2 included covariates of time on dialysis, diabetes, hypertension, perceived stress, 
depressive symptoms, cytokine Factors 1 and 2, and MIP-1β.  Controlling for time on dialysis 
and the comorbidities of diabetes, hypertension, cardiovascular disease, and Factors 1 and 2, a 
significant relationship was found between perceived stress (p = 0.0237), depressive symptoms 
(p = <.0001), and MIP-1β (p = 0.0034) and HRQOL. Finding no significant relationships 
between comorbidities and length of time on dialysis with HRQOL, these variables were 
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excluded and a third model was run with perceived stress, depressive symptoms, Factors 1 and 2 
and MIP-1β. After controlling for Factors 1 and 2, significant correlations remained between 
HRQOL and perceived stress (p = 0.0287), depressive symptoms (p = <.0001), and MIP-1β (p = 
0.0068). Model assumptions were examined for appropriateness of model fit, and the variance 
inflation factor for all models was <5, indicating no multicolinearity in the models. 
Table 4. Multiple Regression Modeling Results for Biobehavioral Measures and HRQOL 
Term Sum of Squares F- Ratio p-Value 
 Model 
1 
Model 
2 
Model 
3 
Model 
1 
Model 
2 
Model 
3 
Model 
1 
Model 
2 
Model 
3 
TOD 40.03 160.41  0.38 1.73  0.54 0.19  
DM 6.46 83.71  0.06 0.90  0.81 0.35  
HTN 11.71 143.03  0.11 1.54  0.74 0.22  
CVD 210.41 198.54  1.98 2.14  0.16 0.15  
PSS 548.72 497.94 466.57 5.17 5.37 5.00 0.03* 0.02* 0.03* 
CES-D 1367.20 1710.78 1620.24 12.89 18.46 17.35 0.0007† <.0001‡ <.0001‡ 
Factor 1 57.17 124.56 94.22 0.54 1.34 1.01 0.47 0.25 0.32 
Factor 2 233.86 173.12 127.48 2.20 1.87 1.37 0.14 0.18 0.25 
Factor 3 24.48   0.23   0.63   
MIP-1β  857.22 727.78  9.25 7.79  0.0034† 0.0068† 
TOD = time on dialysis; DM = diabetes mellitus; HTN = hypertension; CVD = cardiovascular 
disease; PSS = Perceived Stress Score; CES-D = Center for Epidemiologic Studies Depression 
Scale. 
*p  < 0.05, † p < 0.01, ‡ p < 0.0001 
 
Discussion 
  ESRD is a chronic disease with multiple physical and psychological stressors (Yeh & 
Chou, 2007) and long-term stress has been shown to lead to dysregulation of immune responses 
(Yang & Glaser, 2002). In the PNI model biological and behavioral variables and cofactors result 
in biological and behavioral interactions that may alter HRQOL.  
Factor analysis of the cytokine data suggests that pro-inflammatory cytokines have 
correlations with cardiovascular disease and hypertension in patients with ESRD on 
hemodialysis. Atherosclerosis is a pro-inflammatory disorder and increased secretion of pro-
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inflammatory cytokines, including MIP-1β, has been linked to atherosclerosis in prior studies in 
the general population (Cagnin et al., 2009; Cha et al., 2000). A larger sample size for the 
number of variables evaluated in this study may reveal stronger associations between immune 
function and health-related quality of life. Although no significant relationships were found for 
age, race, or cormorbidities with HRQOL, this study suggests that there are behavioral and 
possibly biological interactions that are associated with patients’ perceptions of HRQOL. 
Study participants reported somewhat higher stress levels (15.9, SD = 8.0) than normative 
data (mean = 13.02, SD = 6.35) reported by Cohen and Williamson (1988). Likewise, the mean 
for the CES-D was 16.2 (SD = 12.7), slightly above the cutoff of 16 for depressive symptoms. 
These results are consistent with a large international study that reported an overall rate of 43% 
depressive symptoms in patients on hemodialysis (Lopes et al., 2004). Regression analysis 
showed that depressive symptoms, stress levels, and MIP-1β were significantly related to 
HRQOL. The mean for the FACT-G in this sample was 68.1 (SD = 14.1), lower than the mean of 
80.1 found in the general population (Webster, Cella, & Yost, 2003). This finding is similar to 
findings from other studies investigating quality of life in dialysis patients (Ginieri, Theofilou, 
Synodinou, Tomaras, and Soldatos, 2008; Walters et al., 2002) but, unlike previous studies, no 
significant differences were found between time on dialysis or comorbidities and HRQOL in the 
current study.  
 Both stress and depressive symptoms were negatively related to HRQOL while MIP-1β 
was positively correlated with HRQOL. Irwin and Miller (2007) suggested that cytokines may 
alter information processing in the brain, increasing vulnerability to negative affect. In turn, 
processing stress in a more negative way may contribute to a decrease in perceived quality of 
life. Sample means in this study were lower for IL-1, IL-2, and TNF-α and higher for IL-6 and 
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IFNγ than those reported in normative studies (Kokkonen et al., 2010). Additionally, there was a 
significant correlation between a pro-inflammatory cytokine pattern (Factor 1) and depressive 
symptoms. Prior studies have found correlations between pro-inflammatory cytokines, 
particularly IL-6, and depression (Hung et al., 2010; Irwin & Miller, 2007). Lower levels of 
MIP-1β have been correlated with major depressive disorder. The MIP-1β relationship with 
quality of life scores was marginal in the context of inflated error for multiple testing effects. 
Thus, biological data are entirely exploratory in nature and must be further examined in future 
studies with larger sample sizes. 
Implications 
The mean for depression scores in this study indicates clinical depression when compared 
with the normative data, yet few patients had been prescribed anti-depressive medications. The 
strong correlation with HRQOL and pro-inflammatory cytokines indicates that recognizing and 
addressing depression in patients on hemodialysis could be an important intervention to improve 
the health of these patients. In addition, further research is needed to better understand the ways 
that immune status affects depression or depression affects immune status.  
Cardiovascular disease is the leading cause of mortality and morbidity for patients with 
ESRD (Amann, Ritz, Adamczak, & Ritz, 2003). Improving outcomes and extending survival in 
patients on hemodialysis is an important goal for providers. The links between pro-inflammatory 
cytokines and cardiovascular disease need further investigation to determine the mechanisms 
involved and ultimately to design interventions to improve outcomes.  
Patients on hemodialysis experience physical and psychological stress from many factors 
in their lives. Further research to find interventions to help patients deal with stress could 
influence their HRQOL. 
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In conclusion, research suggests that stress and depression influence immune function in 
other populations and, given the poor outcomes for dialysis patients, it is important to understand 
the complex biobehavioral interactions that may be involved with this population. The PNI 
framework provides a structure to further investigate these phenomena. Although the findings in 
the current study are limited by the small convenience sample, this study provides important 
confirmation about the elevated levels of perceived stress and depressive symptoms and 
decreased quality of life in patients with ESRD on hemodialysis.  
Limitations 
This study was conducted in an urban area in the Southeast, with a much higher 
percentage of African American males than the national hemodialysis population, so findings are 
not necessarily representative of the population of persons with ESRD on hemodialysis. In 
addition, the sample size may not have been large enough to detect meaningful correlations 
among the variables. HRQOL is a complex concept and other variables not measured may affect 
it. Additionally, some vascular access devices for hemodialysis are more susceptible to infection, 
leading to more inflammation; hence, access type might be an important variable to include in 
future analyses. Future studies should continue to explore the complex interactions among 
psychosocial factors, immune phenomena, and quality of life, as well as longer-term health-
related outcomes.  
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